| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Ziihera (zanidatamab-hrii) HER2+ first-line (1L) gastroesophageal adenocarcinoma (GEA) PriorityFast TrackOrphan | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 3 topline data readout example | Ziihera (zanidatamab-hrii) HER2+ first-line (1L) gastroesophageal adenocarcinoma (GEA) PriorityFast TrackOrphan | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 3 topline data readout example | Ziihera (zanidatamab-hrii) HER2+ first-line (1L) gastroesophageal adenocarcinoma (GEA) PriorityFast TrackOrphan | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Jazz Pharmaceuticals plc
$249.29
-10.94 (-4.2%)
B 78Pipeline Score Undervalued Pharma · Commercial
Market Cap
16.18 B
EPS
14.49
P/E Ratio
17.2 $
Value Trade
230.73 M
-1.14 %
Week
-2.4 %
1 Month
4.94 %
3 Month
26.65 %
6 Month
33.83 %
5 Year
1,270.46 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
2.42 M
52 Week Range
122.50 - 266.38
% held by Insiders
4.17 %
% held by Institutions
99.9 %
Enterprise Value
19.35 B
Total Shares
64.89 M
Short %
5.81 %
Float Shares
62.17 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jazz Pharmaceuticals plc
1196Total events
12Upcoming
365Tier-1 (high impact)
2012 – 2030Coverage
Upcoming catalysts 2
TBD
T1Acquisition
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆PDUFA DateZanidatamabApprovedRegulatory Filing
Subscribe to view catalyst details
TBD
◆PDUFA DateZanidatamabApprovedRegulatory Filing
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-08-25 | Ziihera (zanidatamab-hrii) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-08-25 | Ziihera (zanidatamab-hrii) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-08-25 | Ziihera (zanidatamab-hrii) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
B78
Pipeline Score $15.3B
Pipeline ValueUndervalued
Valuation Signal53
Drugs Scored3.1x
rNPV / MCap Top 97%
Mid Cap (rank 29 of 933)
Percentile RankJazz Pharmaceuticals plc holds a solid B-grade pipeline (78/100), with $18.0B risk-adjusted pipeline value, led by GWP42004 in Diabetes Mellitus, Type 2 (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GWP42004 Small molecule | Diabetes Mellitus, Type 2 | Phase 2 | NCT02053272 | 23% | $4.7B | COMPLETED | 207 | - | - | Feb 1, 2016 | - | Dec 20, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Xywav | narcolepsy and idiopathic hypersomnia | Phase 4 | 2026-06-16 | mean time to stable dose idiopathic hypersomnia: 42.1 (14-62) days; mean time to stable dose narcolepsy: 41.8 (12-67) days; patients analyzed: over 13,000 Read More | Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the... Read More | |
Xywav | narcolepsy and idiopathic hypersomnia | Phase 4 | 2026-06-16 | mean time to stable dose idiopathic hypersomnia: 42.1 (14-62) days; mean time to stable dose narcolepsy: 41.8 (12-67) days; patients analyzed: over 13,000 Read More | Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the... Read More | |
Xywav | narcolepsy and idiopathic hypersomnia | Phase 4 | 2026-06-16 | mean time to stable dose idiopathic hypersomnia: 42.1 (14-62) days; mean time to stable dose narcolepsy: 41.8 (12-67) days; patients analyzed: over 13,000 Read More | Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the... Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in JAZZ
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
JAZZ Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
JAZZ▼ -4.2%today
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
Jazz Pharmaceuticals has announced a private offering of $1.0 billion in exchangeable senior notes due 2032, aimed at qualified institutional buyers. The company will also repurchase up to $225 million of its ordinary shares concurrently with the offering. The proceeds from the offering are intended for general corporate purposes, although market conditions may affect the transaction.
Read more →JAZZ▼ -4.2%today
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera®...
Jazz Pharmaceuticals announced FDA approval for Ziihera (zanidatamab-hrii) in combination with tislelizumab and chemotherapy for first-line treatment of advanced HER2-positive gastroesophageal adenocarcinoma. This approval establishes a new standard of care and is based on the HERIZON-GEA-01 trial results, which demonstrated significant improvements in overall and progression-free survival. The approval is significant for patients with limited treatment options.
Read more →JAZZJazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive...
Jazz Pharmaceuticals has announced its acquisition of Actio Biosciences for $820 million upfront, with potential additional payments of up to $500 million. This acquisition includes ABS-1230, a novel therapy for KCNT1+ epilepsy, a rare condition with no current FDA-approved treatments. The deal is expected to close in the fourth quarter of 2026, pending customary conditions.
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2026 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026....
Jazz Pharmaceuticals reported strong financial results for the second quarter of 2026, achieving record revenues of $1.2 billion, a 16% increase year-over-year. The company raised its revenue guidance for the year, anticipating continued growth driven by its key products, including Xywav and Epidiolex. Additionally, Jazz is preparing to launch its new drug Ziihera pending FDA approval.
Read more →JAZZJazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
Jazz Pharmaceuticals has announced that it will report its second quarter financial results on August 3, 2026. The report will be released after the U.S. financial markets close, followed by a management-hosted webcast at 4:30 p.m. ET. Interested parties can register in advance for the call and access a replay via the company's website.
Read more →JAZZJazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license...
Jazz Pharmaceuticals and AbCellera have announced a preclinical collaboration to develop T-cell engaging multispecific antibodies targeted at gastrointestinal cancers and other solid tumors. The agreement includes $56 million in upfront payments and up to $792 million in potential milestone payments. Jazz has the exclusive option to develop any therapeutic antibodies that result from the collaboration, further enhancing its oncology portfolio. This partnership is expected to leverage AbCellera's advanced antibody discovery capabilities to provide novel treatment options for difficult-to-treat cancers.
Read more →JAZZJazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the...
Jazz Pharmaceuticals showcased 11 late-breaking presentations at SLEEP 2026, highlighting the efficacy of Xywav in treating narcolepsy and idiopathic hypersomnia. The research emphasizes the importance of individualized dosing and potential cardiometabolic health benefits associated with Xywav's low-sodium formulation. Findings suggest meaningful health improvements for patients, establishing a comprehensive treatment paradigm that enhances patient quality of life. The data advances scientific understanding of complex sleep disorders, marking a significant milestone for Jazz Pharmaceuticals.
Read more →JAZZJazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Jazz Pharmaceuticals announced that the Phase 3 LAGOON trial for Zepzelca (lurbinectedin) in second-line small cell lung cancer did not meet its primary endpoint of overall survival. Despite this, the safety profile remained consistent with previous data. The company plans to discuss the results with the FDA regarding post-marketing requirements for the second-line indication.
Read more →JAZZJazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP...
Jazz Pharmaceuticals announced that they will present 21 abstracts, including 11 late-breaking ones, at SLEEP 2026, showcasing ongoing research into the treatment of narcolepsy and idiopathic hypersomnia. The data emphasizes the effectiveness of their product, Xywav, which is the first FDA-approved treatment for idiopathic hypersomnia. This substantial presentation underscores the company's dedication to addressing challenging sleep disorders through clinical research and real-world evidence.
Read more →JAZZPhase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial...
Jazz Pharmaceuticals announced the publication of Phase 3 HERIZON-GEA-01 trial results in the New England Journal of Medicine, which showcase the efficacy and safety of Ziihera (zanidatamab-hrii). The trial demonstrated significant improvements in progression-free survival and overall survival outcomes in patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. Additional analyses revealed consistent benefits across different PD-L1 expression levels, reinforcing zanidatamab's clinical potential. The findings could reshape first-line treatment expectations for this cancer indication.
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals has announced its participation in several upcoming investor conferences, including the RBC Global Healthcare Conference and the Jefferies Global Healthcare Conference. These events will feature fireside chats with company management, providing insights into their innovative therapies. Audio webcasts of these discussions will be available on their website.
Read more →JAZZ▲ +7.7%on this news
Jazz Pharmaceuticals Announces First Quarter 2026 Financial ResultsUSA - EnglishUSA - English
Jazz Pharmaceuticals reported a strong financial performance for Q1 2026, achieving total revenues of $1.1 billion, a 19% increase year-over-year. The company highlighted significant growth in its product lines, particularly Xywav and Epidiolex, and announced that zanidatamab's supplemental Biologics License Application was granted Priority Review. Despite a GAAP net loss due to litigation expenses, Jazz reaffirmed its revenue guidance for 2026.
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2026 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2026 (1Q26). "Our first-quarter results reflect...
Jazz Pharmaceuticals reported strong financial results for the first quarter of 2026, with total revenues reaching $1.1 billion, a 19% increase year-over-year. The company highlighted significant growth in its Xywav and Epidiolex products, alongside advancements in its pipeline, particularly with zanidatamab, which has been granted Priority Review by the FDA. The company remains optimistic about its financial guidance for the year, supported by strong commercial execution.
Read more →JAZZJazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals announced the FDA's acceptance of the supplemental Biologics License Application for zanidatamab in combination therapies for HER2-positive gastroesophageal adenocarcinoma. The application is supported by data from the HERIZON-GEA-01 trial, which demonstrated significant clinical benefits. The FDA has set a target action date of August 25, 2026, for the review.
Read more →JAZZJazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
Jazz Pharmaceuticals has announced it will release its first quarter financial results for 2026 on May 5, 2026. The results will be shared after the U.S. markets close, followed by a webcast hosted by company management. This event will provide insights into the company's business and financial status.
Read more →JAZZJazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present three rapid oral and seven poster...
Jazz Pharmaceuticals plc announced its participation in the upcoming ASCO 2026 Annual Meeting, where it will present multiple studies related to zanidatamab and lurbinectedin. The key presentations will focus on zanidatamab's performance in advanced HER2-positive gastroesophageal adenocarcinoma and real-world data on the safety and effectiveness of lurbinectedin in extensive-stage small cell lung cancer. This initiative highlights Jazz's commitment to advancing treatment options through innovative research and collaboration.
Read more →JAZZJazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
Jazz Pharmaceuticals announced the presentation of six abstracts at the 2026 American Academy of Neurology Annual Meeting, highlighting their commitment to addressing rare neurological disorders. The research includes clinical data on Epidiolex for various forms of epilepsy and Xywav for narcolepsy. The presentations aim to enhance understanding of treatment needs in these conditions.
Read more →JAZZJazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
Jazz Pharmaceuticals will participate in the 25th Annual Needham Healthcare Conference on April 15, 2026. Company management will engage in a fireside chat, which will be available via an audio webcast. This event underscores Jazz's commitment to transparency and investor relations.
Read more →JAZZAmerican Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education
The American Nutrition Association has partnered with Jazz Pharmaceuticals to promote evidence-based nutritional education aimed at patients with narcolepsy and idiopathic hypersomnia. This initiative focuses on reducing sodium intake to mitigate cardiovascular risks associated with these conditions. The collaboration seeks to empower patients and equip healthcare providers with the necessary resources for effective patient education.
Read more →JAZZJazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company and its partners will present one oral and six poster presentations at the...
Jazz Pharmaceuticals announced that it will present seven studies at the 2026 AACR Annual Meeting, highlighting advancements in its oncology portfolio. The presentations include new insights into zanidatamab's HER2 biology and emerging data on other therapies such as dordaviprone and JZP898. Specific studies will explore zanidatamab's efficacy in treating various HER2+ cancers and feature innovative clinical trial designs. Overall, this showcases Jazz's commitment to developing effective cancer therapies and contributing to the oncology field.
Read more →JAZZ▲ +13.2%on this news
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial GuidanceUSA - EnglishUSA - English
Jazz Pharmaceuticals reported strong financial results for 2025, with total revenues reaching $4.3 billion, marking a 5% increase year-over-year. The company anticipates completing a supplemental Biologics License Application for zanidatamab in the first quarter of 2026. Additionally, the launch of Modeyso has been promising, contributing significantly to revenue growth. The outlook for 2026 remains positive with projected revenues between $4.25 and $4.50 billion.
Read more →JAZZJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial...
Jazz Pharmaceuticals reported record revenues of $4.3 billion for 2025, marking a 5% year-over-year increase. The fourth quarter alone saw revenues of $1.2 billion, a 10% increase from the previous year. The company anticipates total revenues for 2026 to range between $4.25 billion and $4.50 billion, driven by strong performances from products like Xywav and Epidiolex. Additionally, Jazz is preparing for the submission of a supplemental biologics license application for zanidatamab in HER2+ GEA.
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor conferences: TD Cowen 46th Annual ...
Jazz Pharmaceuticals announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and the Barclays 28th Annual Global Healthcare Conference on March 12, 2026. The company plans to host audio webcasts of the events available on its investor website, with replays archived for 30 days. This engagement reflects Jazz's ongoing focus on innovation and patient-centered therapeutic solutions.
Read more →JAZZJazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
Jazz Pharmaceuticals has announced that it will report its fourth quarter and full year 2025 financial results on February 24, 2026. The results will be shared after the U.S. markets close, followed by a webcast for management to discuss the outcomes. Interested parties can register for the call in advance through the company's website.
Read more →JAZZ▼ -5.4%on this news
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga ...
Jazz Pharmaceuticals has appointed Thomas Riga as Chief Business Officer, effective January 1, 2026. Riga, who joined the company through the acquisition of Chimerix Inc., brings over 25 years of experience in the pharmaceutical sector. His leadership at Chimerix included guiding the successful approval and launch of a therapy for H3K27M-mutant diffuse midline glioma. He is expected to enhance Jazz's corporate development initiatives and strategic partnerships.
Read more →JAZZZiihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating...
Jazz Pharmaceuticals announced positive results from the Phase 3 HERIZON-GEA-01 trial, demonstrating that Ziihera (zanidatamab-hrii) in combination with chemotherapy shows unprecedented median overall survival for patients with HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The study reported a median overall survival benefit of more than seven months compared to the control group, marking a significant advancement in treatment options. Data from the trial, which included 914 patients globally, will be presented at the upcoming ASCO Gastrointestinal Cancers Symposium.
Read more →JAZZJanuary 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Disease Renee Gala, President & CEO Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements
Jazz Pharmaceuticals is participating in the 44th Annual J.P. Morgan Healthcare Conference, showcasing its strategic focus on rare diseases. The company highlighted its strong momentum in approvals, product launches, and substantial revenue guidance for 2025, reflecting its growth potential. However, management cautioned about forward-looking statements that are subject to various risks and uncertainties, particularly related to regulatory approvals and market competition. The emphasis remains on expanding its product portfolio while mitigating risks associated with drug development and market dynamics.
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming Investor EventsUSA - EnglishUSA - English
Jazz Pharmaceuticals has announced its participation in two upcoming investor events: the Zanidatamab HERIZON-GEA-01 Investor Webcast on January 9, 2026, and the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. Audio webcasts of these presentations will be available on the company's website for 30 days following the events. Jazz Pharmaceuticals continues to focus on developing innovative therapies for serious diseases.
Read more →JAZZJazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Jazz Pharmaceuticals will present eight abstracts on Epidiolex at the AES 2025 Annual Meeting, including promising interim results from the EpiCom trial. This trial focuses on behavioral outcomes in patients with tuberous sclerosis complex. The findings highlight the potential of Epidiolex in managing complex epilepsy disorders, emphasizing patient-centered outcomes.
Read more →JAZZJazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Jazz Pharmaceuticals announced that two abstracts featuring key data for Ziihera (zanidatamab-hrii) will be presented at the ASCO GI Symposium in January 2026. The late-breaking Phase 3 HERIZON-GEA-01 trial results indicate that Ziihera in combination with chemotherapy shows significant improvements in progression-free survival for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The company aims to establish Ziihera as the new standard of care for these patients.
Read more →JAZZJazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Jazz Pharmaceuticals will participate in Citi's 2025 Global Healthcare Conference with a fireside chat scheduled for December 2, 2025. The event will be accessible via an audio webcast, which will be archived for 30 days. This participation underscores Jazz's commitment to engaging with investors and promoting its innovative therapies.
Read more →JAZZ▲ +20.6%on this newsshared move
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals announced positive results from the Phase 3 HERIZON-GEA-01 trial for Ziihera (zanidatamab-hrii) in treating HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The trial showed significant improvements in progression-free survival and a strong trend towards overall survival when Ziihera was combined with chemotherapy and the PD-1 inhibitor Tevimbra. The company plans to submit a supplemental BLA in the first half of 2026.
Read more →JAZZJazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Jazz Pharmaceuticals will present five abstracts at the 2025 SNO Annual Meeting, highlighting their research on Modeyso™ (dordaviprone) for treating H3 K27M-mutant diffuse midline glioma. The presentations aim to provide new insights into treatment optimization for patients with this aggressive brain tumor. Modeyso has received FDA approval for patients with progressive disease, reflecting Jazz's commitment to advancing treatment options.
Read more →JAZZJazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial GuidanceUSA - EnglishUSA - English
Jazz Pharmaceuticals reported a 7% year-over-year revenue increase for Q3 2025, driven by strong sales of Epidiolex and Xywav. The company also received FDA approvals for Modeyso, the first treatment for recurrent H3 K27M-mutant DMG, and a combination therapy involving Zepzelca. Despite these successes, Jazz anticipates a net loss for the year, highlighting ongoing challenges in managing operating expenses.
Read more →JAZZJazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
Jazz Pharmaceuticals has appointed Dr. Ted W. Love to its Board of Directors, effective December 1, 2025. Dr. Love, a veteran in the biopharmaceutical industry, has over 30 years of experience and previously led Global Blood Therapeutics. His appointment aligns with Jazz's strategy for growth and innovation, while Kenneth O'Keefe will retire from the Board on the same date.
Read more →JAZZJazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
Jazz Pharmaceuticals has announced that it will report its third quarter financial results for 2025 on November 5, 2025. The report will be followed by a live audio webcast hosted by company management to discuss the results and provide a business update. Interested parties are encouraged to register in advance for the webcast.
Read more →JAZZFDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
The FDA has approved the combination of Zepzelca (lurbinectedin) and atezolizumab (Tecentriq) as a first-line maintenance therapy for adults with extensive-stage small cell lung cancer (ES-SCLC). This approval is based on the Phase 3 IMforte trial, which demonstrated a 46% reduction in disease progression risk and a 27% reduction in mortality risk. The combination therapy is now included in the National Comprehensive Cancer Network guidelines, offering a new treatment option for patients post-induction therapy.
Read more →JAZZJazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
Jazz Pharmaceuticals presented new Phase 4 data and real-world evidence for Xywav at the World Sleep and Psych Congresses. The findings from the DUET trial highlight the treatment's effectiveness in managing symptoms of narcolepsy and idiopathic hypersomnia. Experts emphasized the importance of understanding treatment impacts on patients' daily lives, reinforcing the value of Xywav.
Read more →JAZZModeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Modeyso™ (dordaviprone) is recommended by the National Comprehensive Cancer Network®...
Jazz Pharmaceuticals announced that Modeyso (dordaviprone) has been included in the National Comprehensive Cancer Network (NCCN) Guidelines as a category 2A treatment for recurrent H3 K27M-mutant diffuse high-grade gliomas in both adults and children. Modeyso received accelerated approval from the FDA in August 2025, based on efficacy analyses from several clinical trials. It provides a novel therapeutic option in a challenging clinical landscape, but its continued approval depends on confirming clinical benefits in ongoing studies. Safety concerns include serious adverse reactions and hypersensitivity risks, emphasizing the need for monitoring during treatment.
Read more →JAZZJazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2025 Wells Fargo Healthcare Conference. Company...
Jazz Pharmaceuticals plc has announced its participation in the 2025 Wells Fargo Healthcare Conference. Management will be involved in a fireside chat scheduled for September 3, 2025. An audio webcast will be available for the chat, allowing broader access to investors and stakeholders, with a replay to be archived for 30 days. This highlights the company’s commitment to transparency and engagement with its investor community.
Read more →JAZZJazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Saniona (Nasdaq OMX: SANION) today announce that the companies have entered into a global license...
Jazz Pharmaceuticals has entered an exclusive licensing agreement with Saniona to develop SAN2355, a preclinical asset aimed at treating epilepsy and other indications. The deal grants Jazz worldwide rights to SAN2355, which is designed to selectively activate Kv7.2/Kv7.3 potassium channels, potentially offering an advanced treatment option. Saniona will receive an upfront payment of $42.5 million, along with potential milestone payments and royalties on future sales. This partnership strengthens Jazz's pipeline in neuroscience and highlights their focus on advancing new therapies for epilepsy and neurological conditions.
Read more →JAZZJazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m. IST to provide an...
Jazz Pharmaceuticals is set to host an investor webcast on August 27, 2025, to discuss Modeyso™ (dordaviprone), which received FDA accelerated approval on August 6, 2025. Modeyso is designed for treating adult and pediatric patients with diffuse midline glioma harboring an H3 K27M mutation. This treatment is noteworthy as it is the only option available for this rare and aggressive brain tumor. The webcast will cover clinical data, patient needs, and commercial launch plans for Modeyso.
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2025 and updated financial guidance for 2025. It ...
Jazz Pharmaceuticals reported a total revenue of $1.05 billion in the second quarter of 2025, reflecting a 2% year-over-year increase. The company announced the appointment of Renee Gala as the new President and CEO, effective August 11. Despite the revenue growth, Jazz faced significant losses with a GAAP net loss of $718.5 million and a non-GAAP adjusted net loss of $504.8 million. The company updated its 2025 financial guidance, maintaining expectations for total revenue but projecting continued losses.
Read more →JAZZJazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025,...
Jazz Pharmaceuticals announced it will report its second quarter financial results for 2025 on August 5, 2025. The results will be disclosed after the U.S. financial markets close, followed by a live audio webcast hosted by company management. Participants are encouraged to register in advance for the webcast, which will also have a replay available later on their investor website. The company emphasizes its commitment to developing innovative treatments in various therapeutic areas.
Read more →JAZZJazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer -Selection Follows Robust Succession Process Led by the Board- -Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Director
Jazz Pharmaceuticals has appointed Renee Gala as President and Chief Executive Officer, effective August 11, 2025, following the retirement of Bruce Cozadd. Gala, who has extensive experience in finance and operations, previously served as President and COO and has been instrumental in the company's transformation. The Board's thorough selection process highlights their confidence in Gala's leadership abilities, positioning her to drive further growth and value creation for the company.
Read more →JAZZJazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and...
Jazz Pharmaceuticals has appointed Renee Gala as the new President and CEO, effective August 11, 2025. Gala, who has been with the company since 2020, succeeds co-founder Bruce Cozadd, who will remain Chairperson. The Board expressed confidence in Gala's leadership to drive growth and innovation at Jazz.
Read more →JAZZJazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission (EC) has granted conditional marketing authorization1 for...
Jazz Pharmaceuticals has announced that the European Commission has granted conditional marketing authorization for Ziihera (zanidatamab) to treat adults with unresectable locally advanced or metastatic HER2-positive biliary tract cancer. This authorization is based on positive results from the HERIZON-BTC-01 Phase 2b trial, which demonstrated meaningful responses in patients. Ziihera is the first HER2-targeted treatment approved in the EU for this indication, although the ongoing Phase 3 HERIZON-BTC-302 trial will further verify its clinical benefit. The safety profile of zanidatamab has been evaluated, although there are risks associated with adverse reactions.
Read more →JAZZZepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug...
Jazz Pharmaceuticals announced that the FDA has accepted its supplemental New Drug Application for Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) as a first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC). The decision follows promising results from the Phase 3 IMforte trial, which demonstrated significant improvements in both progression-free and overall survival compared to atezolizumab alone. The FDA has set the Prescription Drug User Fee Act (PDUFA) action date for October 7, 2025, indicating a potential new therapeutic option for patients with limited treatment choices.
Read more →JAZZJazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced late-breaking Phase 4 data evaluating treatment benefits of Xywav® (calcium, magnesium,...
Jazz Pharmaceuticals unveiled late-breaking Phase 4 data at SLEEP 2025, highlighting significant benefits of Xywav in narcolepsy treatment. The XYLO switch study demonstrated meaningful blood pressure reductions when transitioning from high-sodium oxybate to Xywav. Additionally, an interim analysis from the DUET trial showed improvements in excessive daytime sleepiness for patients on higher Xywav doses. While the data is promising, some participants experienced mild to moderate treatment-emergent adverse events.
Read more →JAZZJazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2...
Jazz Pharmaceuticals has reported long-term data from its Phase 2 trial of Ziihera (zanidatamab-hrii) in HER2-positive metastatic gastroesophageal adenocarcinoma. The study showed a median overall survival of 36.5 months and median progression-free survival of 15.2 months after four years of follow-up. The results were presented at ASCO 2025 and published in The Lancet Oncology, highlighting the drug's potential as an effective first-line treatment option. The trial demonstrated a manageable safety profile with no new adverse safety signals identified.
Read more →JAZZJazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs...
Jazz Pharmaceuticals announced positive results from the Phase 3 IMforte study demonstrating that the combination of Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) significantly improves progression-free and overall survival for patients with extensive-stage small cell lung cancer (ES-SCLC). The study showed a median overall survival of 13.2 months compared to 10.6 months for atezolizumab alone. Presented at the ASCO 2025 Annual Meeting, the trial represents a potential new standard of care as a first-line maintenance therapy and supports upcoming FDA application efforts.
Read more →JAZZJazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nineteen abstracts, including eleven late-breaking abstracts will be presented at SLEEP...
Jazz Pharmaceuticals has announced the presentation of nineteen abstracts, including eleven late-breaking ones, at the SLEEP 2025 conference in Seattle. The research focuses on the effectiveness of Xywav, a low-sodium oxybate treatment for narcolepsy and idiopathic hypersomnia. Significant findings, including interim results from the XYLO trial and insights on safety and efficacy, will be highlighted, reflecting Jazz's commitment to advancing treatment for sleep disorders and related comorbidities.
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies...
Jazz Pharmaceuticals plc announced its participation in two upcoming investor conferences, namely the Jefferies Global Healthcare Conference and the Goldman Sachs 46th Annual Global Healthcare Conference. These events are scheduled for June 5 and June 11, 2025, respectively. Audio webcasts of the presentations will be available on the company's investor relations website, with replays available for 30 days. The company's participation in these conferences highlights its ongoing commitment to engaging with investors and conveying its advancements in biopharmaceuticals.
Read more →JAZZ▼ -5.9%on this news· ran to -17% by day 3
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2025 and updated financial guidance for 2025....
Jazz Pharmaceuticals reported its financial results for Q1 2025, achieving total revenues of $898 million, supported by growth in Xywav and Epidiolex sales. The company reaffirmed its revenue guidance for the year at $4.15 to $4.40 billion, reflecting confidence in its commercial portfolio. Jazz completed the submission of a supplemental New Drug Application for Zepzelca in first-line extensive-stage small cell lung cancer, and acquired Chimerix to enhance its late-stage pipeline. However, the company also reported a significant GAAP net loss and a decreased adjusted net income compared to the previous year, influenced by antitrust litigation settlements.
Read more →JAZZJazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company...
Jazz Pharmaceuticals plc has announced its participation in the BofA Securities 2025 Healthcare Conference, scheduled for May 14, 2025. Company management will engage in a fireside chat, which will be available via audio webcast. This initiative reflects Jazz's commitment to transparency and investor communication. Interested parties can access the archived replay of the chat on Jazz Pharmaceuticals' website for a month following the event.
Read more →JAZZJazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
Jazz Pharmaceuticals announced that the CHMP has issued a positive opinion recommending conditional marketing authorization for zanidatamab. This bispecific antibody is intended as a treatment for adults with unresectable, advanced HER2-positive biliary tract cancer, an area currently lacking approved HER2-targeted therapies in the EU. The decision is based on data from the Phase 2b HERIZON-BTC-01 trial, providing optimism for patients previously treated with systemic therapy.
Read more →JAZZJazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for Zepzelca® (lurbinectedin) and...
Jazz Pharmaceuticals presented promising data at the ASCO 2025 Annual Meeting, focusing on advancements in cancer therapies. Noteworthy highlights included statistically significant progression-free and overall survival data for Zepzelca in small cell lung cancer, the potential of Ziihera to change treatment for HER2+ gastroesophageal cancer, and encouraging results for dordaviprone in diffuse glioma. The investor webcast is scheduled for June 10, 2025, to discuss the findings further.
Read more →JAZZJazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after...
Jazz Pharmaceuticals plc announced it will report its first quarter financial results for 2025 on May 6, 2025. Following the release of these results, the management will host a live audio webcast to discuss financial performance and provide updates. Interested parties can access the webcast via the Investors section of the company’s website. This event underscores Jazz Pharmaceuticals' commitment to keeping stakeholders informed about its financial progress.
Read more →JAZZJazz Pharmaceuticals Completes Acquisition of Chimerix -Addition of dordaviprone strengthens Jazz s late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need- DUBLIN
Jazz Pharmaceuticals has successfully completed its acquisition of Chimerix for approximately $935 million, making Chimerix a wholly owned subsidiary. This acquisition brings dordaviprone into Jazz's oncology portfolio, a drug that may serve as the first FDA-approved treatment for H3 K27M-mutant diffuse glioma. Dordaviprone is under Priority Review by the FDA, with a decision expected by August 18, 2025. The integration of Chimerix is seen as a strategic move to address unmet medical needs in rare diseases.
Read more →JAZZJazz Pharmaceuticals Completes Acquisition of Chimerix Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc....
Jazz Pharmaceuticals has successfully completed its acquisition of Chimerix for approximately $935 million. This acquisition adds dordaviprone, a novel treatment for H3 K27M-mutant diffuse glioma, to Jazz's oncology portfolio. The drug is under Priority Review by the FDA, with a potential approval date set for August 18, 2025. The acquisition aims to enhance Jazz's capabilities in addressing rare diseases with significant unmet needs.
Read more →JAZZJazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company...
Jazz Pharmaceuticals plc will participate in the 24th Annual Needham Healthcare Conference on April 9, 2025. The event will feature a fireside chat with company management, aimed at discussing the company's advancements and strategies. An audio webcast of the event will be available on their investor relations website and will be archived for 30 days. This participation highlights Jazz's commitment to innovation and development in the biopharma sector.
Read more →JAZZJazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that seven abstracts from across its neuroscience portfolio will be featured at the 77th...
Jazz Pharmaceuticals presented seven abstracts at the upcoming 2025 AAN Annual Meeting, focusing on their neuroscience portfolio, particularly Xywav and Epidiolex. New results from the Phase 4 DUET trial highlighted significant benefits of Xywav for adults suffering from narcolepsy and idiopathic hypersomnia, showing improvements in sleep quality and daytime symptoms. The efficacy of Epidiolex was also underlined through new patient-reported data. As the first FDA-approved treatment for idiopathic hypersomnia, Xywav aims to address the unmet needs of patients with challenging neurological disorders.
Read more →JAZZJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio -Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term co
Jazz Pharmaceuticals has announced its acquisition of Chimerix for approximately $935 million, or $8.55 per share, aiming to enhance its oncology portfolio. The acquisition includes Chimerix's promising drug, dordaviprone, which is in development for H3 K27M-mutant diffuse glioma, a rare brain tumor. Expected benefits from dordaviprone include filling a significant treatment void, with the FDA granting it Priority Review status. The transaction is expected to close in the second quarter of 2025, but is subject to customary closing conditions and regulatory hurdles.
Read more →JAZZJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix"), today announced the companies have...
Jazz Pharmaceuticals has announced its acquisition of Chimerix for approximately $935 million, focusing on enhancing its oncology portfolio with dordaviprone, a treatment for H3 K27M-mutant diffuse glioma. This acquisition is expected to close in Q2 2025, pending regulatory approval. Dordaviprone has been granted Priority Review by the FDA, with a PDUFA action date set for August 18, 2025.
Read more →JAZZJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025....
Jazz Pharmaceuticals plc has announced a strong financial performance for the full year and fourth quarter of 2024, achieving record revenues of $4.1 billion. The company reported significant growth in its key products, with Xywav and Epidiolex revenues rising year-over-year. Jazz also highlighted the recent approval of Ziihera for 2L HER2+ BTC and is optimistic about its 2025 financial outlook. However, the company noted some challenges with Rylaze sales due to new pediatric treatment protocol updates.
Read more →JAZZJazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45th Annual Health Care Conference. Company...
Jazz Pharmaceuticals plc has announced its participation in TD Cowen's 45th Annual Health Care Conference, where company management will engage in a fireside chat. This event is scheduled for March 5, 2025, and will be accessible via an audio webcast on their investor relations website. The company's commitment to innovation in life-changing medicines will be highlighted during this event, showcasing their work in various therapeutic areas including oncology and neuroscience.
Read more →JAZZ▲ +5.2%on this news
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday,...
Jazz Pharmaceuticals plc has announced that it will report its financial results for the full year and fourth quarter of 2024 on February 25, 2025. The report will be released after the close of U.S. financial markets, followed by a live audio webcast at 4:30 p.m. ET. The company aims to provide updates on its business and financial performance, underscoring its dedication to innovating treatments for serious diseases. Interested parties can access the webcast through the Jazz Pharmaceuticals website.
Read more →JAZZJanuary 2025 rd 43 Annual J.P. Morgan Healthcare Conference Innovating to Transform the Lives of Patients and Their Families Markella EPIDIOLEX patient diagnosed with Dravet syndrome January 2025 Transforming Lives. Rede
Jazz Pharmaceuticals has outlined its strategic vision at the January 2025 J.P. Morgan Healthcare Conference, emphasizing innovation in developing life-changing medicines for patients with serious conditions like Dravet syndrome. The company highlighted its robust pipeline and financial guidance for 2024, projecting significant growth in revenue. Additionally, Jazz is focused on expanding the commercial potential of its product candidates, including Epidiolex and Zepzelca, while aiming to enhance shareholder value. Despite promising developments, the company acknowledged inherent risks tied to regulatory processes and market dynamics.
Read more →JAZZJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan...
Jazz Pharmaceuticals announced that it will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. CEO Bruce Cozadd will give an overview of the company and a business update on January 14, 2025. The webcast will be accessible through the Investors section of Jazz Pharmaceuticals' website, with a replay available for 30 days thereafter. The company aims to innovate and develop transformative medicines for patients with serious diseases.
Read more →JAZZJazz Pharmaceuticals Announces CEO Succession Plan Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed...
Jazz Pharmaceuticals has announced the retirement of CEO Bruce Cozadd, who will step down once a successor is appointed by the end of 2025. Cozadd, a co-founder of the company, has significantly contributed to its growth, leading it to an expected revenue exceeding $4 billion in 2024. The Board will initiate a comprehensive search for a new CEO, focusing on both internal and external candidates. Cozadd will remain as Chairperson of the Board, ensuring continuity in leadership during the transition.
Read more →JAZZJazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced nine company-sponsored Epidiolex® (cannabidiol) posters are being presented at the American...
Jazz Pharmaceuticals announced the presentation of nine abstracts highlighting new real-world evidence for Epidiolex at the American Epilepsy Society 2024 Annual Meeting. Key data include findings from the EpiCom trial showing improvements in behavioral symptom severity in patients with tuberous sclerosis complex. Additional insights from the BECOME surveys indicate favorable outcomes related to seizure frequency and non-seizure symptoms reported by caregivers and nurses. These presentations underscore the positive impact of Epidiolex in treating various treatment-resistant epilepsies.
Read more →JAZZJazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for injection for intravenous use is recommended by ...
Jazz Pharmaceuticals announced that its drug Ziihera has been included in the NCCN Clinical Practice Guidelines for Biliary Tract Cancers (BTC) as a category 2A treatment option. Ziihera, an FDA-approved dual HER2-targeted bispecific antibody, shows a 52% objective response rate based on its clinical trial data. The drug provides a vital new treatment choice for patients with HER2-positive BTC but requires further confirmatory trials for continued approval. Key safety concerns include severe diarrhea and the risk of cardiac issues.
Read more →JAZZJazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m. GMT...
Jazz Pharmaceuticals announced a webcast on December 11, 2024, to discuss Ziihera (zanidatamab-hrii), the first chemotherapy-free dual HER2-targeted bispecific antibody approved by the FDA for biliary tract cancer. The webcast will cover clinical data, patient needs, and commercialization strategies. While Ziihera has been hailed for its innovative approach, there are concerns regarding potential serious adverse reactions that patients may face, impacting ongoing clinical evaluations and treatment protocols.
Read more →JAZZJazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2024 San Antonio Breast...
Jazz Pharmaceuticals announced the presentation of significant research at the upcoming 2024 San Antonio Breast Cancer Symposium and the American Society of Hematology Annual Meeting. The company will showcase advancements related to zanidatamab, particularly its Phase 3 EmpowHER-303 trial for HER2-positive metastatic breast cancer and data from a Phase 1b/2 study. This follows the recent FDA approval of Ziihera for previously treated unresectable metastatic HER2-positive biliary tract cancer. Jazz is focusing on improving treatment standards in oncology and expanding clinical programs in challenging areas.
Read more →JAZZJazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) Ziihera is
Jazz Pharmaceuticals has received FDA accelerated approval for Ziihera (zanidatamab-hrii), a bispecific antibody designed to treat adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). This marks a significant advancement as Ziihera is the first approved treatment of its kind for this patient population, demonstrating a 52% objective response rate. While promising, the drug's ongoing approval depends on further clinical trial results and it carries the risk of serious adverse reactions in some patients.
Read more →JAZZJazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera®...
Jazz Pharmaceuticals announced the FDA's accelerated approval of Ziihera (zanidatamab-hrii) for adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. This marks the first approval of a dual HER2-targeted bispecific antibody for this indication, based on a 52% objective response rate from the HERIZON-BTC-01 clinical trial. The approval is significant as it provides a chemotherapy-free treatment option for patients with limited existing therapies. However, continued approval is contingent on further clinical trials.
Read more →JAZZJazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company...
Jazz Pharmaceuticals has announced its participation in Citi's 2024 Global Healthcare Conference, scheduled for December 3, 2024. Company management will engage in a fireside chat, accessible via audio webcast. This event will allow investors to gain insights into the company's strategies and developments. Jazz remains committed to advancing treatments for serious diseases through its diverse portfolio and innovative pipelines.
Read more →JAZZJazz Pharmaceuticals Announces Third Quarter 2024 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and updated guidance for 2024. Jazz once...
Jazz Pharmaceuticals reported strong financial results for Q3 2024, showcasing a 14% year-over-year revenue increase and overall revenue exceeding $1.05 billion. The company has affirmed its revenue guidance for 2024, estimating between $4.0 to $4.1 billion. Key products such as Xywav and Epidiolex contributed significantly to this growth. Additionally, Jazz plans to submit a supplemental New Drug Application (sNDA) for Zepzelca, indicating a strategic focus on expanding its market presence in oncology.
Read more →JAZZJazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts presenting data from across its sleep portfolio were featured at the...
Jazz Pharmaceuticals presented new data at the Psych Congress 2024 regarding the Phase 4 DUET trial, highlighting the effectiveness of Xywav in treating adults with narcolepsy and idiopathic hypersomnia. The findings showed significant improvements in excessive daytime sleepiness and key sleep outcomes. However, the treatment is associated with common adverse events like nausea and dizziness. Furthermore, Xywav carries risks related to central nervous system depression and abuse potential.
Read more →JAZZJazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024,...
Jazz Pharmaceuticals plc has announced that it will report its third quarter financial results for 2024 on November 6, 2024, following the close of U.S. markets. A live audio webcast is scheduled for that day at 4:30 p.m. ET to discuss the results along with a business update. Stakeholders can access the webcast through the Jazz Pharmaceuticals investor website, and a replay will also be available afterward. The company emphasizes its commitment to innovating medicines for serious diseases.
Read more →JAZZ▲ +5.6%on this news
Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca®...
Jazz Pharmaceuticals announced positive results from a Phase 3 trial evaluating the combination of Zepzelca (lurbinectedin) and atezolizumab as a first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC). The combination therapy showed statistically significant improvement in overall and progression-free survival compared to atezolizumab alone. The company plans to submit a supplemental New Drug Application in the first half of 2025, indicating a strong commitment to bringing this potentially impactful treatment to patients. Preliminary safety data suggested the combination was well-tolerated with no new adverse effects reported.
Read more →JAZZJazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated data, including median progression-free survival (mPFS) and overall survival (OS)...
Jazz Pharmaceuticals has presented updated Phase 2 trial results for zanidatamab, a bispecific antibody targeting HER2, which demonstrated significant efficacy in patients with HER2-positive metastatic gastroesophageal adenocarcinoma. The trial reported a confirmed objective response rate of 84% and a median progression-free survival of 15.2 months. Additionally, the safety profile was deemed manageable, with no new safety signals identified. Jaz pharmaceuticals continues its clinical development with an upcoming Phase 3 trial expected to provide further data in 2025.
Read more →JAZZJazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company, along with its partners, will present five abstracts at the European...
Jazz Pharmaceuticals announced plans to present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024, scheduled for September 13-17 in Barcelona, Spain. The company will showcase new data on zanidatamab, an investigational dual HER2-targeted bispecific antibody, which includes overall survival findings and its application in HER2-positive metastatic gastroesophageal adenocarcinoma. Additionally, data on Zepzelca, an approved treatment for relapsed small cell lung cancer, will be presented, highlighting its safety and efficacy in specific patient populations. The updates from Jazz reflect advancements in their oncology research initiatives and potential future impact on treatment options.
Read more →JAZZJazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present eight abstracts at the 15th European Epilepsy Congress (EEC),...
Jazz Pharmaceuticals announced that they will present eight abstracts at the upcoming European Epilepsy Congress 2024, showcasing data related to Epidiolex treatment. Notably, results from the BECOME caregiver survey indicate significant improvements in both seizure and non-seizure outcomes for patients with Lennox-Gastaut syndrome and Dravet syndrome. The findings are derived from over 2,000 patient experiences, highlighting Epidiolex's potential impact on the quality of life for patients and their caregivers. The presentation is scheduled for September 7-11, 2024, in Rome, Italy.
Read more →JAZZJazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ( Jazz Pharmaceuticals ) today announced the pricing of $850 million aggregate principal amount of 3.125%...
Jazz Pharmaceuticals has announced the pricing of $850 million in 3.125% exchangeable senior notes due 2030, aimed at qualified institutional buyers. The net proceeds are expected to be used primarily for debt prepayments and general corporate purposes. Concurrently, the company repurchased approximately $150 million of its ordinary shares, impacting its existing share repurchase program. The offering and share repurchase are part of Jazz's strategy to optimize its financial structure.
Read more →JAZZ▼ -5.7%on this newsshared move
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases DUBLIN
Jazz Pharmaceuticals has announced a private offering of $850 million in exchangeable senior notes due by 2030. The notes will be offered to qualified institutional buyers, with an option for purchasers to acquire an additional $150 million. Proceeds from the sale are expected to help prepay term loans and repurchase ordinary shares, enhancing the company's financial positioning. However, the completion of share repurchases and the exact terms remain uncertain and dependent on market conditions.
Read more →JAZZ▼ -5.7%on this newsshared move
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the...
Jazz Pharmaceuticals has announced a private offering of $850 million in exchangeable senior notes due 2030, aiming to strengthen its financial position. The offering includes an option for initial purchasers to buy an additional $150 million in notes. Concurrently, the company plans to repurchase up to $150 million of its ordinary shares, contingent on market conditions. Proceeds from the offering will be used for prepaying term loans and general corporate purposes.
Read more →JAZZJazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 open-label, single-arm trial in Japan evaluating the safety ...
Jazz Pharmaceuticals has announced the top-line results of its Phase 3 trial in Japan for its cannabidiol oral solution, intended for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. While the trial did not meet its primary efficacy endpoint, there were numeric improvements noted in several secondary measures and no new safety signals were detected. The company remains committed to its ongoing research and plans to engage with regulatory authorities regarding future steps.
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming September Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Wells Fargo...
Jazz Pharmaceuticals plc has announced its participation in upcoming investor conferences, specifically the Wells Fargo Healthcare Conference on September 4, 2024, and the Bank of America Global Healthcare Conference on September 18, 2024. The company will provide audio webcasts of the events, allowing investors to access the discussions conveniently. This initiative reflects Jazz's ongoing efforts to connect with the investment community and share insights about its business strategies and developments.
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2024 and updated guidance for 2024....
Jazz Pharmaceuticals reported a 15% year-over-year increase in revenue for Q2 2024, reaching over $1 billion, largely driven by the strong performance of its products Xywav, Epidiolex, and Rylaze. The company announced a narrowing of its total revenue guidance for 2024 to between $4.0 and $4.1 billion, while reaffirming its net income guidance. Notably, the U.S. FDA granted Priority Review for zanidatamab, with a PDUFA date set for November 29, 2024. Despite an overall positive outlook, the company adjusted its Oncology guidance lower, although it continues to expect growth in key areas.
Read more →JAZZJazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms....
Jazz Pharmaceuticals has announced the election of Laura Hamill to its Board of Directors during its Annual General Meeting. Hamill is a seasoned professional with 35 years in the pharmaceutical industry, previously holding executive roles at Gilead Sciences and Amgen Inc. The addition of Hamill, alongside other board members, signifies Jazz's ongoing efforts to enhance its board composition and drive shareholder value. The company has also thanked retiring board members Peter Gray and Catherine Sohn for their service.
Read more →JAZZJazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ( Jazz Pharmaceuticals ) today announced that it has completed a repricing of the approximately $2.7 billion...
Jazz Pharmaceuticals has successfully repriced approximately $2.7 billion of its term loans, reducing the applicable margin by 75 basis points, yielding annual interest savings of around $23 million. The company also announced an irrevocable election to fix the settlement method for its 2.000% Exchangeable Senior Notes due 2026, allowing exchanges for cash and shares. This strategic financial maneuver indicates Jazz's commitment to enhancing its capital structure and operational efficiency. However, the company noted that there are inherent risks related to its future financial obligations and the execution of these strategies.
Read more →JAZZJazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 second quarter financial results on Wednesday, July 31, 2024,...
Jazz Pharmaceuticals plc has announced that it will report its financial results for the second quarter of 2024 on July 31, 2024. The results will be shared following the close of U.S. financial markets, and a live audio webcast will be hosted by the company's management at 4:30 p.m. ET. Interested parties are encouraged to register in advance for the webcast, which will also be available for replay. This report underscores the company's ongoing commitment to transparency and communication with its investors.
Read more →JAZZJazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Samantha Pearce, Senior Vice President (SVP), Europe and International, has been...
Jazz Pharmaceuticals has announced the promotion of Samantha Pearce to Chief Commercial Officer, effective August 1, 2024. Pearce, who has over 30 years of experience in the pharmaceutical industry, has been with Jazz since 2020 and has significantly contributed to the company's commercial growth. In her new role, she will oversee Jazz's commercial strategy and operations across the globe, aiming to enhance patient access to transformative treatments. Her leadership is expected to cultivate a performance-driven culture within the organization.
Read more →JAZZJazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and...
Jazz Pharmaceuticals announced top-line results from their Phase 2b trial for suvecaltamide in essential tremor. The drug failed to meet its primary endpoint of statistical significance, although numeric improvements were noted. The safety profile was consistent with previous studies, with only mild to moderate side effects reported. The company is currently analyzing the data and is awaiting results from an ongoing trial for Parkinson's disease tremor.
Read more →JAZZJazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings, from...
Jazz Pharmaceuticals announced long-term follow-up data from the HERIZON-BTC-01 trial, showing significant overall survival rates for zanidatamab in HER2-positive biliary tract cancer. The median overall survival was reported as 15.5 months, with an increase in duration of response noted at 14.9 months. These results highlight the potential of zanidatamab to provide meaningful benefits in patients previously treated for this challenging cancer. The findings support the ongoing clinical development of zanidatamab, which has also received priority review from the FDA for commercialization.
Read more →JAZZJazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that thirteen abstracts, including five late-breaking abstracts, featuring new data from...
Jazz Pharmaceuticals announced that 13 abstracts, including five late-breaking discoveries, will be presented at SLEEP 2024 in Houston, Texas. The presentations will feature data from the Phase 4 XYLO study and analyses of Xywav efficacy in narcolepsy patients. These efforts underline Jazz's commitment to advancing treatment for serious sleep disorders, demonstrating their focus on patient-centered solutions. The company's unique treatment, Xywav, is recognized as the first FDA-approved option for idiopathic hypersomnia in adults.
Read more →JAZZZanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of...
Jazz Pharmaceuticals announced that the FDA has granted Priority Review for zanidatamab, a bispecific antibody targeting HER2-positive metastatic biliary tract cancer. The PDUFA date is set for November 29, 2024. If approved, zanidatamab will be the first HER2-targeted therapy specifically indicated for patients with this condition. The review is based on strong clinical trial data demonstrating a significant response rate among treated patients. This development underscores the urgency for new treatment options in a cancer type with a poor prognosis.
Read more →JAZZJazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee...
Jazz Pharmaceuticals has announced a strategic collaboration with Life Science Cares to enhance social impact through employee volunteerism across the United States. The initiative aims to improve community well-being by engaging employees in addressing poverty and inequality. Life Science Cares will help Jazz harness its employees' passion by providing opportunities for volunteerism. The collaboration reflects Jazz's commitment to support local communities and strengthen nonprofit partnerships.
Read more →JAZZJazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care...
Jazz Pharmaceuticals announced its participation in the BofA Securities 2024 Global Health Care Conference on May 15, 2024. The company's management will engage in a fireside chat that will be accessible via an audio webcast. The webcast will be available for 30 days for those who wish to access the insights shared during the discussion.
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2024 and affirmed guidance for 2024....
Jazz Pharmaceuticals announced its financial results for Q1 2024, reporting a 12% increase in revenue driven by key products like Xywav, Epidiolex, and Rylaze. The oncology segment saw a 13% growth, while the company affirmed its revenue guidance for the year to be between $4.0 and $4.2 billion. However, the reporting period also showed a GAAP net loss of $14.6 million, partly due to higher expenses. The company made notable progress in its pipeline with a BLA submission for zanidatamab, aiming for a possible launch in 2025 or earlier.
Read more →JAZZJazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the...
Jazz Pharmaceuticals has announced that it will present or publish eight abstracts at the upcoming ASCO Annual Meeting from May 31 to June 4, 2024. Key presentations will feature updated data from the pivotal Phase 2b HERIZON-BTC-01 trial, specifically focusing on zanidatamab for HER2-positive metastatic biliary tract cancer. The company's executives are optimistic about zanidatamab's transformative potential in oncology. Full abstracts will be available on May 23, 2024.
Read more →JAZZJazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after ...
Jazz Pharmaceuticals plc will announce its 2024 first quarter financial results on May 1, 2024, after the U.S. markets close. Following the announcement, company management will conduct a live audio webcast to discuss the results and provide a business update. Investors and interested parties can access the webcast on the Jazz Pharmaceuticals website and a replay will be available afterwards.
Read more →JAZZJazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts from across its neuroscience portfolio and pipeline, including two oral...
Jazz Pharmaceuticals announced the presentation of 13 abstracts at the upcoming American Academy of Neurology Annual Meeting. Two oral presentations will reveal data on idiopathic hypersomnia and the long-term effectiveness of Epidiolex in treatment-resistant epilepsies. The company emphasizes its leadership in addressing neurological disorders and the importance of understanding the patient experience. Jazz's products, including Xywav, aim to transform lives despite presenting risks associated with dependence and serious side effects.
Read more →JAZZJazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has completed the rolling submission of a Biologics License Application...
Jazz Pharmaceuticals has completed the rolling submission of a Biologics License Application to the FDA for zanidatamab, aimed at treating previously-treated HER2-positive biliary tract cancer. The application is supported by data from the Phase 2b HERIZON-BTC-01 trial, which showed a confirmed objective response rate of 41.3% in the studied patient cohort. The ongoing Phase 3 HERIZON-BTC-302 trial is also now open for enrollment to further assess zanidatamab's efficacy alongside standard-of-care treatments. If approved, zanidatamab will be the first HER2-targeted therapy specifically for this indication in the U.S.
Read more →JAZZJazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on zanidatamab, a...
Jazz Pharmaceuticals is set to conduct a virtual R&D Day on March 19, 2024, highlighting zanidatamab, a bispecific antibody in late-stage development for HER2-positive cancers. The event will cover the mechanistic rationale and clinical data supporting zanidatamab's further development, particularly for biliary tract cancer, gastroesophageal adenocarcinoma, and breast cancer. Notable external experts will also address current treatment challenges and how zanidatamab may offer new solutions for patients.
Read more →JAZZJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2023 and provided guidance for 2024....
Jazz Pharmaceuticals reported strong financial results for the full year and fourth quarter of 2023, highlighting a total revenue of $3.8 billion, which represents a 27% increase compared to the previous year. Key growth drivers included the successful performance of products such as Xywav, Epidiolex, and Rylaze. The company anticipates multiple late-stage pipeline catalysts for 2024 and has provided guidance indicating continued revenue growth for the upcoming year. GAAP net income for 2023 improved significantly compared to 2022, reflecting effective management strategies and product performance.
Read more →JAZZJazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of Directors. Mr....
Jazz Pharmaceuticals has appointed Patrick Kennedy to its Board of Directors effective March 1, 2024. Kennedy, who has over 30 years of experience in high-growth organizations, will also serve on the Audit Committee. His appointment is part of Jazz's ongoing effort to renew its Board, with a focus on increasing diversity. Current chairman and CEO Bruce Cozadd expressed optimism about Kennedy's expertise aligning with Jazz's mission to enhance shareholder value and patient care.
Read more →JAZZJazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer Mr. Johnson Brings Over 35 Years of Financial and Operating Experience to Leadership Team DUBLIN
Jazz Pharmaceuticals has appointed Philip Johnson as the new Chief Financial Officer, effective March 1, 2024. Johnson, who has over 35 years of experience in finance, previously held a leadership position at Eli Lilly and Company. His responsibilities at Jazz will include overseeing financial reporting, accounting, investor relations, and risk management. The company's leadership has expressed optimism about his ability to contribute to the growth and diversification of Jazz's global business.
Read more →JAZZJazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and ...
Jazz Pharmaceuticals has appointed Philip Johnson as the new Chief Financial Officer, effective March 1, 2024. Johnson, who has over 35 years of financial experience, previously held senior positions at Eli Lilly. His role will encompass overseeing financial reporting, risk management, and investor relations, as the company aims to enhance shareholder value and diversify its global business.
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming March Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: TD Cowen's...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced its participation in two upcoming investor conferences in March 2024: TD Cowen's 44th Annual Health Care Conference and the Leerink Partners Global Biopharma Conference. Audio webcasts of these presentations will be available on the company's website, and replays will be accessible for 30 days. This participation highlights Jazz's commitment to investor engagement and showcasing its biopharmaceutical portfolio.
Read more →JAZZJazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday,...
Jazz Pharmaceuticals announced it will report its 2023 full year and fourth quarter financial results on February 28, 2024, after the U.S. markets close. A live audio webcast is scheduled for 4:30 p.m. ET to discuss the financial results along with a business update. Interested participants can access the webcast through the company's investor relations website, where a replay will also be available afterward.
Read more →JAZZJazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) today announced that the companies have signed a definitive agreement under...
Jazz Pharmaceuticals has signed a definitive agreement with Redx Pharma to acquire global rights to its KRAS inhibitor program for $10 million upfront, with the potential for up to $870 million in milestone payments. This agreement aims to enhance Jazz's early-stage oncology pipeline and address the high unmet need for effective treatments targeting KRAS mutations. The collaboration will involve advancing candidates through IND-enabling studies, emphasizing a joint commitment to developing innovative cancer therapies.
Read more →JAZZJazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational...
Jazz Pharmaceuticals announced that its Phase 2 trial of JZP150 in adults with post-traumatic stress disorder (PTSD) did not meet its primary endpoint, showing no statistically significant reduction in PTSD symptoms compared to placebo. Key secondary endpoints were also not achieved, leading the company to indicate that additional development of JZP150 for PTSD is unlikely. Despite some mild to moderate treatment-emergent adverse events reported, no new safety signals were identified. The findings will be shared with the medical community in the future.
Read more →JAZZJazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan...
Jazz Pharmaceuticals has announced that it will webcast its corporate presentation at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. CEO Bruce Cozadd will present an overview of the company along with a business and financial update. The presentation will be accessible through the Investors section of Jazz Pharmaceuticals' website. A replay will also be available for 30 days after the conference, enhancing investor access to the information shared.
Read more →JAZZJazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted...
Jazz Pharmaceuticals presented updated Phase 2a trial data for zanidatamab at SABCS 2023, showing promising results in patients with HER2+/HR+ metastatic breast cancer. The therapy, combined with palbociclib and fulvestrant, achieved a progression-free survival rate of 67% at six months and a median progression-free survival of 12 months. The trial involved heavily pre-treated patients, highlighting the need for additional treatment options in this population. The safety profile of the regimen was manageable, mirroring the efficacy observed in the study.
Read more →JAZZJazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nine company-sponsored presentations, including five late-breaking abstracts, will be...
Jazz Pharmaceuticals will present nine company-sponsored abstracts at the 2023 American Epilepsy Society annual meeting, focusing on the long-term real-world outcomes of Epidiolex in treatment-resistant epilepsy. The data includes post-hoc analyses from both the Expanded Access Program and the GWPCARE6 Open-Label Extension trial, showcasing the drug's effectiveness in patients with tuberous sclerosis complex. The presentation aims to further establish the evidence for Epidiolex and address its impact on patients' daily lives.
Read more →JAZZJazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2023 San Antonio Breast...
Jazz Pharmaceuticals has announced its upcoming presentations, including two abstracts at the 2023 San Antonio Breast Cancer Symposium and 11 at the ASH Annual Meeting. Notably, the data will showcase the investigational bispecific antibody zanidatamab for treating HER2+/HR+ metastatic breast cancer. The company also emphasizes its commitment to improving standards of care in blood cancers and is set to present real-world findings regarding Zepzelca in small cell lung cancer. These events highlight the firm's continued focus on advancing novel treatments in oncology.
Read more →JAZZJazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2023 and provided business updates....
Jazz Pharmaceuticals reported strong financial results for the third quarter of 2023, achieving total revenues of $972 million, which represents a 3% increase from the same period last year. The company raised its revenue guidance for the year, crediting robust sales from key products like Xywav and Epidiolex. Additionally, Jazz plans to initiate the rolling submission for zanidatamab focused on second-line biliary tract cancers this year. Despite the positive outlook, potential competition for Xywav and a slight decrease in adjusted net income from the previous year could pose challenges.
Read more →JAZZJazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research...
Jazz Pharmaceuticals and MD Anderson Cancer Center have announced a five-year collaboration to evaluate zanidatamab, an investigational HER2-targeted bispecific antibody, in various HER2-expressing cancers. The partnership aims to leverage MD Anderson's research expertise and Jazz's drug development capabilities to explore zanidatamab's use as a monotherapy and in combination treatments. Notably, the ongoing studies seek to address unmet medical needs in areas with limited current options, such as early-stage breast cancer. The collaboration is expected to commence in late 2023 or early 2024 and continues from a previous partnership focusing on hematologic cancers.
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming November Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following upcoming investor conferences:...
Jazz Pharmaceuticals has announced its participation in several upcoming investor conferences, including the Jefferies London Healthcare Conference and the Evercore ISI HealthCONx Conference. These events will provide the company's management with opportunities to engage with investors and discuss their strategic initiatives. Audio webcasts of the presentations will be available for those unable to attend live. The conferences are part of Jazz's ongoing effort to enhance communication with stakeholders about its innovative healthcare solutions.
Read more →JAZZJazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 third quarter financial results on Wednesday, November 8, 2023,...
Jazz Pharmaceuticals plc has announced that it will report its financial results for the third quarter of 2023 on November 8, 2023. A live audio webcast will follow the report at 4:30 p.m. ET for management to discuss the results and provide updates. The company continues to emphasize its commitment to developing life-changing medicines for serious diseases.
Read more →JAZZJazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adults with Narcolepsy at World Sleep 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new data that examine the comorbid risk of cardiovascular disease in patients with narcolepsy ...
Jazz Pharmaceuticals presented new data on the cardiovascular risks associated with narcolepsy and idiopathic hypersomnia, emphasizing the importance of low-sodium treatment options. The TENOR study revealed that patients transitioning to Xywav, a low-sodium oxybate, reported improved sleep quality and reduced morning grogginess. The findings were announced at the World Sleep 2023 Congress and aim to inform healthcare providers about managing cardiovascular health in patients with sleep disorders.
Read more →JAZZJazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 14 abstracts from across its sleep medicine...
Jazz Pharmaceuticals announced the presentation of 14 abstracts at the World Sleep 2023 Congress, which showcases its advancements in sleep medicine. Among the presentations are findings from the TENOR study on dosing strategies for oxybate treatment in narcolepsy and insights from the CV-RHYTHM study highlighting cardiovascular comorbidities in patients with idiopathic hypersomnia. The company aims to increase awareness around the connection between sleep disorders and cardiovascular health, demonstrating its commitment to improving treatment options. The abstracts will contribute to ongoing research and development in the field.
Read more →JAZZ▲ +5.3%on this newsshared move
Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with partners, will present six abstracts including data from trials...
Jazz Pharmaceuticals announced it will present six abstracts at the ESMO 2023 Congress, highlighting promising data for its investigational therapies. Notable findings include data on the bispecific antibody zanidatamab in HER2-targeted biliary tract and gastric cancers, as well as presentations related to Zepzelca in small cell lung cancer. The company aims to advance its solid tumor portfolio through its innovative research initiatives. These presentations underscore Jazz's commitment to improving treatment for challenging cancer types.
Read more →JAZZJazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission (EC) has granted marketing authorization for Enrylaze® (JZP458;...
Jazz Pharmaceuticals has received marketing authorization from the European Commission for Enrylaze (JZP458), a recombinant Erwinia asparaginase treatment for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). The approval addresses the needs of patients who are hypersensitive to E. coli-derived asparaginase, providing an important new option for completing their treatment regimens. Enrylaze shows promising efficacy and safety based on a Phase 2/3 trial conducted with pediatric and adult patients. The treatment will be available throughout the European Union and select European countries.
Read more →JAZZJazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences. TD Cowen 3rd ...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced its participation in three upcoming investor conferences, highlighting its ongoing commitment to engage with investors. The conferences include the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit, the 2023 Cantor Fitzgerald Global Healthcare Conference, and the BofA Securities 2023 CNS Therapeutics Virtual Conference. The events will feature live webcasts to further increase accessibility to the company's mission and developments in the neuropsychiatry and CNS therapeutic fields.
Read more →JAZZJazz Pharmaceuticals Announces Key Update to Leadership Team Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, has been promoted to President and Chief Operating...
Jazz Pharmaceuticals has announced the promotion of Renee Galá to President and Chief Operating Officer, effective October 1, 2023. Galá, who previously served as Chief Financial Officer, will take on her new role following Dan Swisher's retirement, who will aid in the transition as a strategic advisor. Galá brings over two decades of experience from notable life science companies and is expected to lead Jazz towards further growth and innovation in delivering therapies for patients. The company is also commencing an external search for a new Chief Financial Officer.
Read more →JAZZJazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at...
Jazz Pharmaceuticals showcased six abstracts at Psych Congress 2023 focusing on their sleep medicine portfolio. Key findings highlighted the positive effects of oxybate on sleep quality and architecture in narcolepsy patients, confirming its efficacy across dosing regimens. The company emphasized its dedication to addressing challenging sleep disorders, including idiopathic hypersomnia. These presentations underlie Jazz's role in developing effective treatments that can significantly improve patient quality of life.
Read more →JAZZJazz Pharmaceuticals to Participate in Citi's 18th Annual BioPharma Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Citi Annual BioPharma Conference in Boston. Company...
Jazz Pharmaceuticals plc announced its participation in the Citi Annual BioPharma Conference scheduled for September 7, 2023, in Boston. Company management will engage in a fireside chat that will be accessible via an audio webcast. This event highlights Jazz Pharmaceuticals' ongoing commitment to the biopharmaceutical sector and their innovative approach to developing medicines for serious diseases. The company aims to provide updates on their diverse portfolio and pipeline during this conference.
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance – Strong execution delivered second quarter 2023 total revenues of $957 million – – Commercial excellence drove continued adoption of low-sodium...
Jazz Pharmaceuticals plc reported its second quarter 2023 financial results, revealing total revenues of $957 million, a 3% increase from the previous year. The company raised its full year financial guidance, bolstered by strong sales growth of products such as Xywav and Epidiolex. Bruce Cozadd, the CEO, highlighted a disciplined capital allocation strategy and the ongoing development of their oncology portfolio, which is projected to approach $1 billion in sales. Additionally, Jazz's pipeline includes promising advancements like zanidatamab with key data readouts expected by the end of 2024.
Read more →JAZZJazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 second quarter financial results on Wednesday, August 9, 2023,...
Jazz Pharmaceuticals has announced that it will report its 2023 second quarter financial results on August 9, 2023, after U.S. markets close. The company will host a live audio webcast later that day to discuss the results and provide a business update. Investors and interested parties are encouraged to register in advance for the webcast. Jazz Pharmaceuticals is known for its commitment to developing innovative medicines in neuroscience and oncology.
Read more →JAZZJazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use...
Jazz Pharmaceuticals has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for JZP458, a recombinant Erwinia asparaginase. This treatment is recommended as part of a multi-agent regimen for patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who experience hypersensitivity to E. coli-derived asparaginase. The CHMP’s endorsement is a step toward potential marketing authorization in Europe, following the drug's earlier approval by the FDA in the U.S. in 2021.
Read more →JAZZJazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor...
Jazz Pharmaceuticals and Zymeworks have reported positive data from the Phase 2b HERIZON-BTC-01 trial for zanidatamab in HER2-amplified biliary tract cancers (BTC). Results presented at ASCO 2023 show a confirmed objective response rate of 41.3% and a median duration of response of 12.9 months. The trial indicates that zanidatamab may provide a significant clinical benefit over standard chemotherapy, which has historically low response rates. The drug is designed as a first-and-only HER2-targeted treatment for this aggressive cancer type, with an ongoing trial aiming to further evaluate overall survival outcomes.
Read more →JAZZJazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that seven abstracts featuring new data from across its sleep medicine portfolio will be...
Jazz Pharmaceuticals has announced the presentation of seven abstracts highlighting new data from its sleep medicine portfolio at the SLEEP 2023 conference. These abstracts focus on innovative treatments for sleep disorders such as narcolepsy and idiopathic hypersomnia, emphasizing the importance of Xywav, a low-sodium treatment option for patients. The company aims to enhance the understanding of these conditions and address the associated health risks. Jazz Pharmaceuticals continues to demonstrate its leadership and dedication to improving the lives of patients dealing with sleep disorders.
Read more →JAZZJazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 Goldman Sachs Global Healthcare Conference....
Jazz Pharmaceuticals plc announced its participation in the 2023 Goldman Sachs Global Healthcare Conference, where company management will engage in a fireside chat on June 13, 2023. An audio webcast of this discussion will be accessible on the company's website, and a replay will be available for 30 days following the event. This participation reflects Jazz's commitment to innovation and engagement with investors in the biopharmaceutical sector.
Read more →JAZZJazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a webcast to review the zanidatamab biliary tract cancers (BTC) data being featured in an oral...
Jazz Pharmaceuticals is set to host a webcast on June 2, 2023, to present data on zanidatamab, targeted at biliary tract cancers. The drug has shown a confirmed objective response rate of 41.3% in previous trials. The webcast will feature insights from Dr. Shubham Pant and Jazz's senior management on zanidatamab's development and commercialization. Given the lack of approved HER2-targeted therapies for this cancer type, the presentation is anticipated to highlight significant findings on zanidatamab's efficacy and safety.
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2023, affirmed 2023 financial guidance and...
Jazz Pharmaceuticals reported a strong financial performance for the first quarter of 2023, with total revenues rising to $892.8 million, a 10% increase from the previous year. Key products, especially Xywav and Rylaze, showed significant growth in net sales, indicating robust commercial execution. The company affirmed its 2023 financial guidance and highlighted an enhanced pipeline set to deliver multiple late-stage data readouts by 2024. Overall, Jazz showcases a strong position in both its existing products and future developments.
Read more →JAZZJazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 RBC Capital Markets Global Healthcare...
Jazz Pharmaceuticals has announced its participation in the 2023 RBC Capital Markets Global Healthcare Conference, scheduled for May 16, 2023. The company's management will partake in a fireside chat, which will be available via an audio webcast. This initiative reflects the company's commitment to investor engagement and transparency in their ongoing business operations.
Read more →JAZZJazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023 Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results,...
Jazz Pharmaceuticals has announced the acceptance of nine abstracts for presentation at the upcoming ASCO 2023 Annual Meeting, highlighting their investigational bispecific drug zanidatamab. This drug shows promising results in treating HER2-positive biliary tract cancers, which currently lack FDA-approved therapies. The company's presentations reflect its robust oncology pipeline and dedication to advancing treatment options. Jazz will also host an investor webcast to review the key findings from their presentations.
Read more →JAZZJazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 first quarter financial results on Wednesday, May 10, 2023,...
Jazz Pharmaceuticals has announced that it will report its 2023 first quarter financial results on May 10, 2023, following the close of U.S. financial markets. Management will host a live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. Interested parties can register for the call in advance on the company's website, and a replay will also be available. Jazz is committed to developing transformative medicines within the fields of neuroscience and oncology.
Read more →JAZZJazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three...
Jazz Pharmaceuticals is set to present eleven abstracts at the upcoming 75th Annual American Academy of Neurology Meeting in Boston. The presentations will focus on advancements in treatment for sleep disorders, epilepsy, and movement disorders, showcasing the company's ongoing commitment to addressing significant medical needs. Three of the abstracts will be delivered as oral presentations, emphasizing the company's research in idiopathic hypersomnia and essential tremor. The event serves as a platform for Jazz to educate the audience about their impactful therapies and ongoing research efforts.
Read more →JAZZJazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart Health Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an expansion of its support of the American Heart Association (Association) to provide the...
Jazz Pharmaceuticals has announced an expanded partnership with the American Heart Association to raise awareness about the link between sleep disorders and cardiovascular health. The initiative will provide resources, including an educational website and a patient video series, focusing on the risks that sleep disorders pose to heart health. This comes in light of research showing that individuals with conditions like narcolepsy are at a significantly higher risk for stroke and heart attacks. Through this collaboration, the American Heart Association aims to educate both patients and healthcare professionals about effective management strategies.
Read more →JAZZJazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American...
Jazz Pharmaceuticals announced that it will present five new abstracts at the 2023 AACR Annual Meeting, showcasing data on Zepzelca (lurbinectedin), zanidatamab, and JZP898. Highlights include promising research into the effectiveness of lurbinectedin in small cell lung cancer and the investigational bispecific antibody zanidatamab, which targets HER2. The ongoing development aims to improve cancer treatment outcomes, particularly for cancers with significant unmet needs. This announcement underscores Jazz’s commitment to advancing cancer therapies and their clinical pipeline.
Read more →JAZZJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2022 and provided financial...
Jazz Pharmaceuticals reported a strong financial performance for 2022, achieving record revenues of $3.7 billion, representing an 18% increase from the previous year. The company experienced notable growth driven by its key commercial franchises, particularly Xywav for narcolepsy and idiopathic hypersomnia. Despite these successes, Jazz reported a GAAP net loss, although it improved its operational efficiency and reduced debt. The company remains committed to advancing its pipeline with new candidates and maintaining its Vision 2025 goals.
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming March Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming investor conferences: Cowen 43rd...
Jazz Pharmaceuticals plc has announced its participation in several upcoming investor conferences, including the Cowen 43rd Annual Health Care Conference and the J.P. Morgan 12th Annual Napa Valley Biotech Forum. These events provide the company with an opportunity to connect with investors and discuss their diverse portfolio and commitment to developing life-changing medicines. Jazz Pharmaceuticals focuses on therapeutic areas like neuroscience and oncology, aiming to provide novel treatment options for patients worldwide.
Read more →JAZZJazz Pharmaceuticals to Report 2022 Fourth Quarter and Full Year Financial Results on March 1, 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 fourth quarter and full year financial results on Wednesday,...
Jazz Pharmaceuticals plc announced it will report its 2022 fourth quarter and full year financial results on March 1, 2023, after the U.S. markets close. The company will host a live audio webcast at 4:30 p.m. ET to discuss these results and provide a business update. Interested parties are encouraged to register in advance for the webcast and a replay will be available afterward. The announcement underscores the ongoing business activities of Jazz Pharmaceuticals in the biopharmaceutical sector.
Read more →JAZZJazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, ...
Jazz Pharmaceuticals and Zymeworks have reported promising results from a Phase 2 trial of zanidatamab for HER2-expressing metastatic gastroesophageal adenocarcinoma. The trial demonstrated an 84% overall survival rate at 18 months and a confirmed objective response rate of 79%. Median progression-free survival was reported at 12.5 months. The ongoing Phase 3 trial, HERIZON-GEA-01, could support future regulatory submissions for zanidatamab as a treatment option combining with chemotherapy.
Read more →JAZZJazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41st Annual J.P. Morgan...
Jazz Pharmaceuticals has announced that it will webcast its corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference. The presentation, scheduled for January 9, 2023, will be led by CEO Bruce Cozadd and will include an overview of the company's business and financial updates. Following the live presentation, a replay of the webcast will be available on the company's website for 30 days. This event highlights Jazz Pharmaceuticals' commitment to engaging with investors and sharing important business information.
Read more →JAZZTransforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related t
41st Annual J.P. Morgan Healthcare Conference Innovating to Transform the Lives of Patients and Their Families January 9, 2023 Grace Epidiolex patient Exhibit 99.1 Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation con
Read more →JAZZJazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DU
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DUBLIN and VANCOUVER, Dec. 21, 2022 Jazz Pharmaceuticals pl
Read more →JAZZJazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies Jazz Pharmaceuticals plc (NASDAQ: JAZZ) today announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex ®)...
Real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) Caregiver Survey presented at the 2022 American Epilepsy Society Annual Meeting expands evidence behind Epidiolex treatment in adult and pediatric patients Caregivers of Lennox-Gastaut Syndrome and Dr
Read more →JAZZJazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations, including...
Data from six abstracts to be presented, including new long-term Phase 3 results and two real-world analyses of U.S. caregiver-reported seizure and non-seizure outcomes in patients prescribed Epidiolex ® (cannabidiol) DUBLIN , Nov. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals p
Read more →JAZZJazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental Biologics License...
Rylaze dosing options provide sustained asparaginase activity throughout the entire course of treatment for adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma DUBLIN , Nov. 18, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) to
Read more →JAZZJazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2022, and raised the mid-point of 2022 total...
DUBLIN , Nov. 9, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the third quarter of 2022, and raised the mid-point of 2022 total revenue guidance. "Our execution across our business continues to chart a clear path to deliveri
Read more →JAZZJazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts will be presented at the American Society of Hematology (ASH) Annual...
Key data includes results for intravenous administration of Rylaze ® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients DUBLIN , Nov. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today ann
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming November Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming investor conferences: Jefferies...
DUBLIN , Nov. 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference on Tuesday, November 15, 2022 5 th Annual Evercore ISI HealthC
Read more →JAZZJazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 third quarter financial results on Wednesday, November 9, 2022,...
DUBLIN , Oct. 26, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2022 third quarter financial results on Wednesday, November 9, 2022 , after the close of the U.S. financial markets. Company management will host a live audio w
Read more →JAZZJazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody Jazz to obtain exclusive development and commercialization rights in k
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymework
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming September Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming investor conferences: Citi's 17th ...
DUBLIN , Aug. 31, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will participate in the following upcoming investor conferences: Citi's 17 th Annual BioPharma Conference on Wednesday, September 7, 2022 2022 Wells Fargo Healthcare
Read more →JAZZJazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex®...
Trial is the first randomized, controlled clinical trial evaluating cannabidiol to treat children and adolescents living with a developmental and epileptic encephalopathy known as Epilepsy with Myoclonic-Atonic Seizures DUBLIN , Aug. 18, 2022 /PRNewswire/ -- Jazz Pharmaceuticals
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance1 and...
DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance 1 and provided business updates. "We've had a highly productive second quarter across commercial, R&D
Read more →JAZZJazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 second quarter financial results on Wednesday, August 3, 2022,...
DUBLIN , July 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2022 second quarter financial results on Wednesday, August 3, 2022 , after the close of the U.S. financial markets. Company management will host a live audio we
Read more →JAZZJazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 RELEASE MSS1 trial (NCT04657666) evaluating nabiximols...
Nabiximols oromucosal spray continues to be evaluated in ongoing clinical trials in multiple sclerosis spasticity DUBLIN , June 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced top-line results from the Phase 3 RELEASE MSS1 trial ( NCT04657666 )
Read more →JAZZJazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, developed and conducted in close collaboration with...
Oral presentation confirms patients achieved clinically meaningful nadir serum asparaginase activity throughout the course of Rylaze treatment with intramuscular dosing regimen administered 25/25/50 mg/m 2 on Monday/Wednesday/Friday DUBLIN , June 7, 2022 /PRNewswire/ -- Jazz Pha
Read more →JAZZJazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June...
DUBLIN , June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022 , at 11:00 a.m. PT / 2:00 p.m. ET / 7:00 p.m. IST in New York . An audio webcast of
Read more →JAZZJazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 17 new abstracts from across its neuroscience...
Seventeen abstracts debut new data across narcolepsy and idiopathic hypersomnia DUBLIN , June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company and its partners will present 17 new abstracts from across its neuroscience portfolio a
Read more →JAZZJazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present seven abstracts at the American Society of...
Key data includes ASCO oral presentation of data from the Rylaze ® (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 trial in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN , May 12, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) toda
Read more →JAZZ▼ -7.1%on this newsshared move
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has completed the divestiture of Sunosi® (solriamfetol) in the U.S. to Axsome...
DUBLIN , May 9, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it has completed the divestiture of Sunosi ® (solriamfetol) in the U.S. to Axsome Therapeutics, Inc. (Nasdaq: AXSM ). Under the terms of the agreement, Jazz received an upfront pay
Read more →JAZZJazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist Jazz licenses development and commercializati
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist Jazz licenses development and commercialization rights in U.S., Europe and other territories; Sumitom
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2022, raised 2022 financial guidance and provided...
DUBLIN , May 4, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the first quarter of 2022, raised 2022 financial guidance and provided business updates. "We're pleased to raise our top- and bottom-line guidance, driven by our c
Read more →JAZZJazz Pharmaceuticals to Participate in the BofA Securities 2022 Global Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2022 Global Healthcare Conference on ...
DUBLIN , May 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company will participate in the BofA Securities 2022 Global Healthcare Conference on Tuesday, May 10, 2022 , at 12:40 p.m. PT / 3:40 p.m. ET / 8:40 p.m. IST in Las Vegas . An a
Read more →JAZZJazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 first quarter financial results on Wednesday, May 4, 2022, after ...
DUBLIN , April 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2022 first quarter financial results on Wednesday, May 4, 2022 , after the close of the U.S. financial markets. Company management will host a live audio webca
Read more →JAZZJazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and collaboration partner Redx Pharma (AIM: REDX) today presented data showing the pan-RAF kinase inhibitor,...
Novel, investigational drug JZP815 inhibited tumor growth in several RAS- and BRAF-mutated solid tumor models, and demonstrated enhanced activity when combined with other MAPK pathway inhibitors Jazz plans to submit an investigational new drug application (IND) for JZP815 this y
Read more →JAZZJazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFN INDUKINE Molecule Werewolf to receive $15 mil
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFN INDUKINE Molecule Werewolf to receive $15 million upfront payment, with potential for up to $1.26 billi
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming April Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming investor conferences: J.P. Morgan ...
DUBLIN , March 29, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company will participate in the following upcoming investor conferences: About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) is a global biopharmaceutical co
Read more →JAZZJazz Pharmaceuticals Announces Agreement to Divest Sunosi (solriamfetol) to Axsome Therapeutics Jazz to receive $53 million upfront cash payment, and royalty rights Transaction designed to ensure uninterrupted patient ac
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi (solriamfetol) to Axsome Jazz to receive $53 million upfront cash payment, and royalty rights Transaction designed to ensure uninterrupted patient access to Sunosi Jazz remains committed to neuroscience with growing fra
Read more →JAZZJazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals ( GW ) – a world leader in discovering, developing and delivering...
Construction begins on a new state-of-the-art manufacturing facility at Kent Science Park designed to support the manufacture of regulatory approved cannabis-based medicines This represents a significant commitment to the UK by GW Pharmaceuticals, now part of Jazz Pharmaceutical
Read more →JAZZJazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca® (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the first patient was enrolled in EMERGE-201, a Phase 2 clinical trial evaluating the safety...
Open-label basket trial will assess the safety and efficacy of Zepzelca in patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination deficient tumors DUBLIN , March 24, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc
Read more →JAZZJazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that pre-clinical data on JZP815, an investigational, next-generation pan-RAF kinase...
DUBLIN , March 8, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that pre-clinical data on JZP815, an investigational, next-generation pan-RAF kinase inhibitor, will be presented as a poster at the American Association for Cancer Research (AACR) 202
Read more →JAZZJAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2021 and provided financial...
DUBLIN , March 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the full year and fourth quarter of 2021 and provided financial guidance for 2022. "2021 was a transformative year for Jazz, delivering over $3 billion in revenu
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming March Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming virtual investor conferences:...
DUBLIN , Feb. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company will participate in the following upcoming virtual investor conferences: Cowen 42 nd Annual Health Care Conference on Monday, March 7, 2022 Needham Virtual Neuroscie
Read more →JAZZJazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 fourth quarter and full year financial results on Tuesday, March ...
DUBLIN , Feb. 15, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2021 fourth quarter and full year financial results on Tuesday, March 1, 2022 , after the close of the U.S. financial markets. Company management will host a li
Read more →JAZZJazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing Schedule Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company has completed the submission of a Supplemental Biologics License Application ...
DUBLIN , Feb. 2, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company has completed the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval for a Monday/Wednesd
Read more →JAZZ▲ +9%on this news
Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader Announces $5 billion revenue target for 2025 Confirms 202
Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader Announces $5 billion revenue target for 2025 Confirms 2021 revenue expected to be within previously announced guid
Read more →JAZZLancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive data from the Phase 3 multicenter, placebo-controlled, double-blind, randomized...
DUBLIN , Jan. 5, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced positive data from the Phase 3 multicenter, placebo-controlled, double-blind, randomized withdrawal study of Xywav ® (calcium, magnesium, potassium, and sodium oxybates) oral solution f
Read more →JAZZJazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced Bruce Cozadd, chairman and chief executive officer, will present virtually as part of the...
DUBLIN , Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced Bruce Cozadd , chairman and chief executive officer, will present virtually as part of the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 , from 2:15 – 2:55
Read more →JAZZU.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Exclusivity (ODE)...
DUBLIN , Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Exclusivity (ODE) for Xywav ® (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatm
Read more →JAZZJazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the safety...
DUBLIN , Dec. 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of
Read more →JAZZJazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a global Phase 2b clinical trial evaluating the...
DUBLIN , Dec. 15, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patient has been enrolled in a global Phase 2b clinical trial evaluating the safety and efficacy of suvecaltamide (also known as JZP385), a highly selective modulator of
Read more →JAZZPharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer PharmaMar (MSE: PHM) and partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the initiation of a confirmatory Phase 3 clinical trial,...
MADRID and DUBLIN , Dec. 13, 2021 /PRNewswire/ -- PharmaMar (MSE: PHM) and partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the initiation of a confirmatory Phase 3 clinical trial, LAGOON, evaluating Zepzelca ® (lurbinectedin) for the treatment of patients with re
Read more →JAZZJazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced initial positive results from a Phase 2/3 trial of intramuscular (IM) administration of...
DUBLIN , Dec. 12, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced initial positive results from a Phase 2/3 trial of intramuscular (IM) administration of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric patients w
Read more →JAZZJazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations, including...
DUBLIN , Dec. 1, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that six company-sponsored Epidiolex ® (cannabidiol) oral solution presentations, including one late-breaking abstract, will be debuted at the upcoming 2021 American Epilepsy Society (A
Read more →JAZZJazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient was enrolled in a Phase 3 clinical trial evaluating Zepzelca®...
DUBLIN , Nov. 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patient was enrolled in a Phase 3 clinical trial evaluating Zepzelca ® (lurbinectedin) in combination with the PD-L1 inhibitor Tecentriq ® (atezolizumab) as a first-line
Read more →JAZZJazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2021 and updated financial guidance for 2021....
DUBLIN , Nov. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the third quarter of 2021 and updated financial guidance for 2021. "Last year, we set the ambitious corporate objective of completing five key commercial launches
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming November Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will virtually participate in the following upcoming investor conferences:...
DUBLIN , Nov. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will virtually participate in the following upcoming investor conferences: Jefferies London Healthcare Conference on Tuesday, November 16, 2021 Evercore ISI HealthCON
Read more →JAZZJazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will be...
DUBLIN , Nov. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that 16 new data abstracts from across its hematology/oncology development program will be presented at the 63 rd American Society of Hematology (ASH) Annual Meeting, which will be held
Read more →JAZZJazz Pharmaceuticals to Report 2021 Third Quarter Financial Results on November 9, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 third quarter financial results on Tuesday, November 9, 2021...
DUBLIN , Oct. 26, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2021 third quarter financial results on Tuesday, November 9, 2021 after the close of the U.S. financial markets. Company management will host a live audio webca
Read more →JAZZJazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m. ET / 9:30...
DUBLIN , Sept. 13, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on Xywav ® (calcium, magnesium, potassium and sodium oxybates)
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming September Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences:...
DUBLIN , Sept. 8, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will participate in the following upcoming virtual investor conferences: BofA Virtual Global Healthcare Conference 2021 on Wednesday, September 15, 2021 Cantor Virtu
Read more →JAZZJazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav® (calcium, magnesium,...
DUBLIN , Aug. 12, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav ® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adul
Read more →JAZZGW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex GW Pharmaceuticals ( GW ), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines and now part of Jazz ...
LONDON , Aug. 10, 2021 /PRNewswire/ -- GW Pharmaceuticals ("GW"), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines and now part of Jazz Pharmaceuticals plc (Nasdaq: JAZZ ), today announces that the UK Medicines and Healthcare P
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2021 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2021 and affirmed non-GAAP adjusted financial...
DUBLIN , Aug. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the second quarter of 2021 and affirmed non-GAAP adjusted financial guidance for 2021. "As we enter what we expect to be a period of sustained growth, I have neve
Read more →JAZZNational Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network® (NCCN) added Rylaze™ (asparaginase erwinia...
DUBLIN , July 22, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the National Comprehensive Cancer Network ® (NCCN) added Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to the Clinical Practice Guidelines in Oncology (NCCN Guide
Read more →JAZZJazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 second quarter financial results on Tuesday, August 3, 2021...
DUBLIN , July 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2021 second quarter financial results on Tuesday, August 3, 2021 after the close of the financial markets. Company management will host a live audio webcast at
Read more →JAZZJazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Tuesday, July 20, 2021 at 4:30 p.m. ET / 9:30 p.m....
DUBLIN , July 13, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will host a webcast on Tuesday, July 20, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), w
Read more →JAZZJazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Approval under U.S. FDA s Real
Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Approval under U.S. FDA s Real-Time Oncology Review program represents an important ther
Read more →JAZZJazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug...
U.S. Food and Drug Administration published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy by means of greater safety compared to Xyrem ® (sodium oxybate)
Read more →JAZZJazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today updated its full year 2021 financial guidance to incorporate the GW Pharmaceuticals (GW) business,...
DUBLIN , June 17, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today updated its full year 2021 financial guidance to incorporate the GW Pharmaceuticals (GW) business, which the Company acquired on May 5, 2021. "We expect 2021 to be another exciting, productive
Read more →JAZZJazz Pharmaceuticals and Leading Cancer Organizations Collaborate to Launch First and Only Digital Hub Focused Exclusively on Emotional, Social and Physical Health Needs of Small Cell Lung Cancer Community Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Nothing Small About It (www.nothingsmallaboutit.com), an online program...
DUBLIN , June 14, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the launch of Nothing Small About It ( www.nothingsmallaboutit.com ), an online program developed with consultation from leading cancer organizations Cancer Care, GO2 Foundation for Lu
Read more →JAZZJazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from...
DUBLIN , June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021, the 35 th annual meeting of the Associated Pro
Read more →JAZZJazz Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference on June 2, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its senior management team will provide a company overview and business and financial...
DUBLIN , May 26, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that its senior management team will provide a company overview and business and financial updates at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 , at 1:00 p.
Read more →JAZZJazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its investigator sponsors will present four new abstracts at the virtual American ...
DUBLIN , May 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it and its investigator sponsors will present four new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4 – June 8, 2021 and five abst
Read more →JAZZJazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc DUBLIN
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc DUBLIN, May 5, 2021 Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ( GW ), a leader in the science, development and commercializa
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2021 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2021 and affirmed financial guidance for 2021....
DUBLIN , May 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the first quarter of 2021 and affirmed financial guidance for 2021. "Demand for Xywav is strong, as both patients and physicians embrace the health benefits associ
Read more →JAZZJazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its senior management team will provide a company overview and business and financial...
DUBLIN , May 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that its senior management team will provide a company overview and business and financial updates at the following virtual investor conferences: Interested parties may access the live
Read more →JAZZJazz Pharmaceuticals Announces Closing of Senior Secured Notes Offering DUBLIN
Jazz Pharmaceuticals Announces Closing of Senior Secured Notes Offering DUBLIN, April 29, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the Company or Jazz ) today announced the closing of its previously announced offering (the Offering ) of $1.5 billion in aggregate principal
Read more →JAZZGW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals LONDON and DUBLIN
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals LONDON and DUBLIN, April 23, 2021 GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today announced that GW s shareholders voted to approve the acquisition of
Read more →JAZZJazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the Company or Jazz ) today announced the pricing of the previously announced offering (the Offering )...
DUBLIN , April 22, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) (the "Company" or "Jazz") today announced the pricing of the previously announced offering (the "Offering") of $1.5 billion in an aggregate principal amount of 4.375% senior secured notes due 2029 (t
Read more →JAZZJazz Pharmaceuticals Prices $1.5 Billion Million Senior Secured Notes Offering DUBLIN
Jazz Pharmaceuticals Prices $1.5 Billion Million Senior Secured Notes Offering DUBLIN, April 22, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the Company or Jazz ) today announced the pricing of the previously announced offering (the Offering ) of $1.5 billion in an aggregate
Read more →JAZZJazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 study of XywavTM (calcium, magnesium, potassium, and sodium ...
DUBLIN , April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced positive results from the Phase 3 study of Xywav TM (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia, which will be pre
Read more →JAZZJazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes DUBLIN
Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes DUBLIN, April 20, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the Company ) announced today that its wholly owned subsidiary, Jazz Securities Designated Activity Company (the Issuer ), is commenc
Read more →JAZZJazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 first quarter financial results on Tuesday, May 4, 2021 after...
DUBLIN , April 19, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2021 first quarter financial results on Tuesday, May 4, 2021 after the close of the financial markets. Company management will host a live audio webcast at 4:3
Read more →JAZZJazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation and...
Jazz submitted to FDA the clinical study report for the Phase 3 study of Xywav in a double-blind, multicenter, placebo-controlled, randomized withdrawal study evaluating the efficacy and safety of Xywav in adult patients with idiopathic hypersomnia in December 2020 under rolling
Read more →JAZZJazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos®...
DUBLIN , March 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos ® (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-relat
Read more →JAZZJazz Pharmaceuticals Announces Participation at the 10th Annual J.P. Morgan Napa Valley Forum Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 10th Annual J.P. Morgan Napa...
DUBLIN , March 22, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will webcast its corporate presentation at the 10th Annual J.P. Morgan Napa Valley Forum. Bruce Cozadd , chairman and chief executive officer, will provide an overvi
Read more →JAZZForward-Looking Statements "Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995 This communication contains forward-looking statements regarding Jazz Pharmaceuticals and GW Pharmaceuticals,
Statement Under The Private Securities Litigation Reform Act of 1995 This communication contains forward-looking statements regarding Jazz Pharmaceuticals and GW Pharmaceuticals, including, but not limited to, statements related to the anticipated acquisition of GW Pharmaceutica
Read more →JAZZJazz Pharmaceuticals Announces Participation at Cowen 41st Annual Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Cowen 41st Annual Healthcare...
DUBLIN , Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will webcast its corporate presentation at the Cowen 41st Annual Healthcare conference. Bruce Cozadd , chairman and chief executive officer, will provide an overview
Read more →JAZZJazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial...
DUBLIN , Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021. "In 2020, we made meaningful progress toward our goal to significantly grow an
Read more →JAZZJazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Leerink 10th Annual Global...
DUBLIN , Feb. 17, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will webcast its corporate presentation at the Leerink 10 th Annual Global Healthcare Conference. Bruce Cozadd , chairman and chief executive officer, will provide an
Read more →JAZZJazz Pharmaceuticals Completes Submission of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application (sNDA) to...
DUBLIN , Feb. 16, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the completion of the rolling submission for the supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for Xywav™ (calcium,
Read more →JAZZJazz Pharmaceuticals to Report 2020 Fourth Quarter Financial Results on February 23, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 fourth quarter and full year financial results on Tuesday,...
DUBLIN , Feb. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2020 fourth quarter and full year financial results on Tuesday, February 23, 2021 , after the close of the financial markets. Company management will host a live
Read more →JAZZJazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex , the first and only FDA
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex , the first and only FDA-approved prescription cannabidiol medicine and a potenti
Read more →JAZZRelevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the virtual J.P. Morgan Annual Health Care Conference on
Relevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the virtual J.P. Morgan Annual Health Care Conference on Bruce C. Cozadd - Jazz Pharmaceuticals plc - Co-Founder, distinct pleasure today to share an update on our significant accomplishm
Read more →JAZZJazz Pharmaceuticals Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 39th Annual J.P. Morgan...
DUBLIN , Jan. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will webcast its corporate presentation at the 39 th Annual J.P. Morgan Healthcare Conference. Bruce Cozadd , chairman and chief executive officer, will provide an ove
Read more →JAZZJazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has initiated the submission of a Biologics License Application (BLA) to the ...
DUBLIN , Dec. 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company has initiated the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for JZP-458 for use as
Read more →JAZZJazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter,...
DUBLIN , Dec. 3, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, randomized, controlled study evaluating Zepzelca™ (lurbinectedin) in combination with doxoru
Read more →JAZZJazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of Directors Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jennifer Cook and Mark D. Smith, M.D. have been appointed to the Company's Board of...
DUBLIN , Nov. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that Jennifer Cook and Mark D. Smith , M.D. have been appointed to the Company's Board of Directors, effective December 1, 2020 . "We are excited to welcome two industry leaders to th
Read more →JAZZJazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the following virtual healthcare...
DUBLIN , Nov. 10, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will webcast its corporate presentation at the following virtual healthcare conference: A live audio webcast of the presentation may be accessed from the Investors se
Read more →JAZZData at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals' Commitment to Advancing Hematology/Oncology Research Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 11 company-sponsored abstracts, in addition to two abstracts from collaboration trials...
DUBLIN , Nov. 5, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that 11 company-sponsored abstracts, in addition to two abstracts from collaboration trials with The University of Texas MD Anderson Cancer Center (MD Anderson), one abstract from a coo
Read more →JAZZJazz Pharmaceuticals Announces Third Quarter 2020 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2020 and updated its 2020 financial guidance. We...
DUBLIN , Nov. 2, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the third quarter of 2020 and updated its 2020 financial guidance. "We delivered strong financial results this quarter, with increasingly diversified revenues fue
Read more →JAZZJazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) ( SpringWorks ) today announced that Jazz Pharmaceuticals...
DUBLIN and STAMFORD, Conn. , Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX ) ("SpringWorks") today announced that Jazz Pharmaceuticals Ireland Limited ("Jazz") and SpringWorks have entered into an asset pur
Read more →JAZZJazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the publication of the global Phase 3 double-blind, placebo-controlled,...
DUBLIN , Oct. 20, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the publication of the global Phase 3 double-blind, placebo-controlled, randomized-withdrawal, multicenter study of Xywav™ (calcium, magnesium, potassium and sodium oxybates) oral solu
Read more →JAZZJazz Pharmaceuticals Announces Webcast for Xywav Investor Update Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, October 26, 2020 at 4:30 p.m. EDT / 8:30 p.m. ...
DUBLIN , Oct. 19, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will host a webcast on Monday, October 26, 2020 at 4:30 p.m. EDT / 8:30 p.m. GMT to provide investors with an update on Xywav™ (calcium, magnesium, potassium, and sodi
Read more →JAZZJazz Pharmaceuticals to Report 2020 Third Quarter Financial Results on November 2, 2020 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 third quarter financial results on Monday, November 2, 2020,...
DUBLIN , Oct. 19, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2020 third quarter financial results on Monday, November 2, 2020 , after the close of the financial markets. Company management will host a live audio webcast i
Read more →JAZZNew Data for Zepzelca™ (lurbinectedin) to be Presented at IASLC 2020 North America Conference on Lung Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its partner PharmaMar (MSE: PHM) today announced they will present new data for Zepzelca™ (lurbinectedin) ...
DUBLIN , Oct. 14, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) and its partner PharmaMar (MSE: PHM) today announced they will present new data for Zepzelca™ (lurbinectedin) in small cell lung cancer (SCLC) at the International Association for the Study of Lung Ca
Read more →JAZZJazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 double-blind, multicenter, placebo-controlled,...
DUBLIN , Oct. 8, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced positive top-line results from the Phase 3 double-blind, multicenter, placebo-controlled, randomized withdrawal study evaluating the efficacy and safety of an investigational use of Xyw
Read more →JAZZJazz Pharmaceuticals Launches Initiative to Help Educate People Living with Rare Form of Leukemia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Find the Right Fit (FindTheRightFit-sAML.com), a U.S. patient education program ...
DUBLIN , Sept. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the launch of Find the Right Fit ( FindTheRightFit-sAML.com ), a U.S. patient education program developed in consultation with the Myelodysplastic Syndromes (MDS) Foundation, Inc. and
Read more →JAZZJazz Pharmaceuticals Announces New Sleep Health Collaboration Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its support of the American Heart Association's sleep health educational content aimed at...
DUBLIN , Sept. 15, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced its support of the American Heart Association's sleep health educational content aimed at improving the health and well-being of those struggling with healthy sleep or those living wi
Read more →JAZZJazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: ...
DUBLIN , Sept. 9, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX) to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP ki
Read more →JAZZJazz Pharmaceuticals Announces Participation at Three Upcoming Virtual Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor...
DUBLIN , Sept. 8, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences: A live audio webcast of each presentation may be accessed from the Investors s
Read more →JAZZJazz Pharmaceuticals to Present New Data on Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Sunosi® (solriamfetol) at Virtual SLEEP 2020 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 10 abstracts will be presented at Virtual SLEEP 2020, the 34th annual meeting of the...
DUBLIN , Aug. 27, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that 10 abstracts will be presented at Virtual SLEEP 2020, the 34 th annual meeting of the Associated Professional Sleep Societies (APSS) from August 28-30 . The presentations will deb
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2020 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2020 and updated its 2020 financial guidance. I...
DUBLIN , Aug. 4, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the second quarter of 2020 and updated its 2020 financial guidance. "I am proud that we delivered strong financial and operational results above our expectations
Read more →JAZZJazz Pharmaceuticals Announces U.S. FDA Approval of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium,...
DUBLIN , July 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21 , 2020 for the treatment of cataplexy or
Read more →JAZZJazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 second quarter financial results on Tuesday, August 4, 2020,...
DUBLIN , July 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2020 second quarter financial results on Tuesday, August 4, 2020 , after the close of the financial markets. Company management will host a live audio webcast i
Read more →JAZZNational Comprehensive Cancer Network® adds Zepzelca™ (lurbinectedin) to Clinical Practice Guidelines in Oncology Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Zepzelca™ (lurbinectedin) was added by the National Comprehensive Cancer Network (NCCN®) ...
DUBLIN , July 13, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that Zepzelca ™ (lurbinectedin) was added by the National Comprehensive Cancer Network (NCCN ® ) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for small cell lun
Read more →JAZZJazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced along with its partner PharmaMar (MSE: PHM) that the U.S. Food and Drug Administration (FDA)...
DUBLIN , June 15, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced along with its partner PharmaMar (MSE: PHM) that the U.S. Food and Drug Administration (FDA) approved Zepzelca ™ (lurbinectedin) for the treatment of adult patients with metastatic sma
Read more →JAZZJazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ( Jazz Pharmaceuticals ) today announced the pricing of $850 million aggregate principal amount of 2.000%...
DUBLIN , June 9, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 2.000% exchangeable senior notes due 2026 in a private offering (the "offering") by Jazz Investments I
Read more →JAZZJazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the Issuer ), intends to...
DUBLIN , June 8, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $850 million aggregate principal amount of
Read more →JAZZJazz Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor...
DUBLIN , May 27, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences: A live audio webcast of each presentation may be accessed from the Investors se
Read more →JAZZJazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its partners will present seven new abstracts at the virtual American Society of...
DUBLIN , May 14, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it and its partners will present seven new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from May 29-June 2, 2020 and six abstracts at the vi
Read more →JAZZJazz Pharmaceuticals Announces Appointment Of Kim Sablich As Executive Vice President, General Manager Of North America Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Kim Sablich as executive vice president, general manager of North America, ...
DUBLIN , May 11, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the appointment of Kim Sablich as executive vice president, general manager of North America , effective June 1, 2020. In this role, Ms. Sablich will lead Jazz's newly formed North Amer
Read more →JAZZJazz Pharmaceuticals Announces Participation at Upcoming Virtual Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor...
DUBLIN , May 6, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences: A live audio webcast of each presentation may be accessed from the Investors sec
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2020 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2020 and updated 2020 financial guidance. During...
DUBLIN , May 5, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the first quarter of 2020 and updated 2020 financial guidance. "During this unprecedented time, I am proud of the commitment of our Jazz employees to supporting th
Read more →JAZZJazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic...
DUBLIN , April 29, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease (VOD) post-hematopoietic stem-cell transplantation (HSCT) in high-ris
Read more →JAZZJazz Pharmaceuticals to Report 2020 First Quarter Financial Results on May 5, 2020 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 first quarter financial results on Tuesday, May 5, 2020, after...
DUBLIN , April 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2020 first quarter financial results on Tuesday, May 5, 2020 , after the close of the financial markets. Company management will host a live audio webcast imme
Read more →JAZZJazz Pharmaceuticals Provides COVID-19 Business Update Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today provided an update regarding the impact of COVID-19 on its business and the actions it is taking to...
DUBLIN , March 31, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today provided an update regarding the impact of COVID-19 on its business and the actions it is taking to mitigate the spread of this virus. "Jazz provides essential medicines to patients around the
Read more →JAZZJazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the ...
"We developed JZP-258 to be a safer and long-term treatment option for patients. JZP-258 represents between 1,000 and 1,500 milligrams daily reduction of sodium for patients currently treated with Xyrem, depending on the dose," said Robert Iannone , M.D., M.S.C.E., executive vice
Read more →JAZZJazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following investor...
DUBLIN , Feb. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will webcast its corporate presentations at the following investor conferences: A live audio webcast of each presentation may be accessed from the Investors section o
Read more →JAZZJazz Pharmaceuticals Announces Full Year And Fourth Quarter 2019 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2019 and provided financial...
DUBLIN , Feb. 25, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the full year and the fourth quarter of 2019 and provided financial guidance for 2020. "With more than $2 billion of revenue and double-digit top- and bottom-lin
Read more →JAZZPharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the U.S. Food and Drug Administration (FDA) accepted for filing with...
MADRID and DUBLIN , Feb. 17, 2020 /PRNewswire/ -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announce that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the New Drug Application (NDA) seeking accelerated approval for lu
Read more →JAZZJazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 fourth quarter and full year financial results on Tuesday,...
DUBLIN , Feb. 11, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2019 fourth quarter and full year financial results on Tuesday, February 25, 2020 , after the close of the financial markets. Company management will host a liv
Read more →JAZZPharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the waiting period under the Hart-Scott-Rodino Antitrust Improvements...
MADRID and DUBLIN , Jan. 22, 2020 /PRNewswire/ -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announce that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended "HSR", with respect to the exclusive license agreement fo
Read more →JAZZJazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on...
DUBLIN , Jan. 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January 21, 2020 seeking marketing approval for JZP-258, an investigational medicine for the
Read more →JAZZJazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission approved Sunosi® (solriamfetol) to improve wakefulness and...
DUBLIN , Jan. 20, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the European Commission approved Sunosi ® (solriamfetol) to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy (with or without cataplexy)
Read more →JAZZRelevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the J.P. Morgan Healthcare Conference in San Francisco, California on
Relevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the J.P. Morgan Healthcare Conference in San Francisco, California on January 13, 2020: Bruce Cozadd, Chairman & CEO, Jazz Pharmaceuticals plc I have to say in 2019 we achieved record re
Read more →JAZZJazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 38th Annual J.P. Morgan ...
DUBLIN , Jan. 6, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Bruce Cozadd , chairman and chief executive o
Read more →JAZZJazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in the pivotal Phase 2/3 clinical study for JZP-458, ...
DUBLIN , Dec. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patient has been enrolled in the pivotal Phase 2/3 clinical study for JZP-458, a recombinant Erwinia asparaginase molecule that uses a novel Pseudomonas fluorescens expr
Read more →JAZZPharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq:JAZZ) today announced that PharmaMar and Jazz Pharmaceuticals Ireland Limited have entered...
MADRID and DUBLIN , Dec. 19, 2019 /PRNewswire/ -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that PharmaMar and Jazz Pharmaceuticals Ireland Limited have entered into an exclusive license agreement for lurbinectedin in the United States . Un
Read more →JAZZJazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use...
DUBLIN , Nov. 15, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorisation of solriamfetol to
Read more →JAZZJazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at three upcoming investor...
DUBLIN , Nov. 14, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will webcast its corporate presentations at three upcoming investor conferences. A live audio webcast of each presentation may be accessed from the Investors section
Read more →JAZZJazz Pharmaceuticals to Highlight Growing Hematology Oncology Pipeline at ASH 2019 Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 15 abstracts sponsored by Jazz Pharmaceuticals, including one oral presentation, one...
DUBLIN , Nov. 7, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that 15 abstracts sponsored by Jazz Pharmaceuticals, including one oral presentation, one abstract from a collaboration trial with MD Anderson Cancer Center (MD Anderson) and two abstra
Read more →JAZZJazz Pharmaceuticals Announces Third Quarter 2019 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2019 and updated 2019 financial guidance. In the...
DUBLIN , Nov. 5, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the third quarter of 2019 and updated 2019 financial guidance. "In the third quarter, we delivered strong revenue and adjusted EPS growth ahead of our expectation
Read more →JAZZJazz Pharmaceuticals to Report 2019 Third Quarter Financial Results on November 5, 2019 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 third quarter financial results on Tuesday, November 5, 2019,...
DUBLIN , Oct. 22, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2019 third quarter financial results on Tuesday, November 5, 2019 , after the close of the financial markets. Company management will host a live audio webcast
Read more →JAZZJazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in an exploratory Phase 2 clinical trial evaluating...
DUBLIN , Oct. 10, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patient has been enrolled in an exploratory Phase 2 clinical trial evaluating the ability of defibrotide to prevent neurotoxicity in patients with relapsed or refractory
Read more →JAZZJazz Pharmaceuticals Survey Highlights Prevalence of Misinformation and Misperception About Narcolepsy Among Americans Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the results of a consumer survey of more than 1,000 Americans measuring public perception and ...
DUBLIN , Sept. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the results of a consumer survey of more than 1,000 Americans measuring public perception and knowledge of sleep disorders like narcolepsy. Narcolepsy is a serious condition that is o
Read more →JAZZJazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that positive data from the Phase 3 study of its investigational medicine, JZP-258, for the...
DUBLIN , Sept. 25, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that positive data from the Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adults with narcolepsy wer
Read more →JAZZJazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, September 25, 2019 at 9:00 p.m. EDT/2:00 a....
DUBLIN , Sept. 18, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will host a webcast on Wednesday, September 25, 2019 at 9:00 p.m. EDT /2:00 a.m. IST ( September 26 , 2019) to provide investors with a business update, including dat
Read more →JAZZJazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...
DUBLIN , Aug. 27, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. A live audio webcast of each presentation may be accessed from the Investors sect
Read more →JAZZJazz Pharmaceuticals Announces Acquisition of Cavion, Inc. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the acquisition of Cavion, Inc. through a merger with a Jazz subsidiary. Under the terms of...
DUBLIN , Aug. 12, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the acquisition of Cavion, Inc. through a merger with a Jazz subsidiary. Under the terms of the agreement, the former Cavion shareholders receive an upfront payment of $52.5 million an
Read more →JAZZJazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Phase 1 study of its recombinant crisantaspase molecule, JZP-458, met its efficacy...
DUBLIN , Aug. 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Phase 1 study of its recombinant crisantaspase molecule, JZP-458, met its efficacy and safety objectives. The company plans to initiate a single-arm, pivotal Phase 2/3 study ev
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2019 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2019 and updated 2019 financial guidance. 2019...
DUBLIN , Aug. 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the second quarter of 2019 and updated 2019 financial guidance. "2019 has been notable for significant execution and accomplishments across all aspects of our bus
Read more →JAZZJazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 second quarter financial results on Tuesday, August 6, 2019,...
DUBLIN , July 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2019 second quarter financial results on Tuesday, August 6, 2019 , after the close of the financial markets. Company management will host a live audio webcast i
Read more →JAZZJazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a definitive agreement under which Jazz has acquired Redx...
DUBLIN , July 10, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company has signed a definitive agreement under which Jazz has acquired Redx Pharma's (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors
Read more →JAZZJazz Pharmaceuticals Announces Webcast for Sunosi Investor Update Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Tuesday, July 2, 2019 at 4:30 p.m. EDT/9:30 p.m. IST...
The investor webcast will include an overview of narcolepsy and OSA from invited physician experts as well as a Sunosi overview from the company's senior management. A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals w
Read more →JAZZJazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Drug Enforcement Agency (DEA) has designated solriamfetol, also known as...
DUBLIN , June 17, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the U.S. Drug Enforcement Agency (DEA) has designated solriamfetol, also known as Sunosi , as a Schedule IV medicine. With U.S. Food and Drug Administration (FDA) approval on Marc
Read more →JAZZJazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Robert Iannone, M.D., M.S.C.E., as executive vice president, research and...
DUBLIN , June 3, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the appointment of Robert Iannone , M.D., M.S.C.E., as executive vice president, research and development, effective May 29, 2019 . Dr. Iannone will lead Jazz's growing global R&D organ
Read more →JAZZJazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that it will present data from across its hematology/oncology portfolio and pipeline at the...
DUBLIN , May 16, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that it will present data from across its hematology/oncology portfolio and pipeline at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31-J
Read more →JAZZJazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that 14 abstracts sponsored by Jazz Pharmaceuticals and one abstract from an...
DUBLIN , May 9, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that 14 abstracts sponsored by Jazz Pharmaceuticals and one abstract from an investigator-sponsored trial will be presented at the 33 rd Annual Meeting of the Associated Professional Sle
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2019 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2019 and reaffirmed 2019 financial guidance. In...
DUBLIN , May 7, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the first quarter of 2019 and reaffirmed 2019 financial guidance. "In the first quarter of 2019, we delivered strong top- and bottom-line growth and continued our
Read more →JAZZJazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019, after...
DUBLIN , April 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019 , after the close of the financial markets. Company management will host a live audio webcast imme
Read more →JAZZJazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the global, double-blind, placebo-controlled,...
DUBLIN , March 26, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced positive top-line results from the global, double-blind, placebo-controlled, randomized-withdrawal, multicenter Phase 3 study evaluating the efficacy and safety of JZP-258 for the tre
Read more →JAZZJazz Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Cowen and Company 39th...
DUBLIN , March 5, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the Cowen and Company 39th Annual Healthcare Conference in Boston, MA. Matt Young , executive vice president and chie
Read more →JAZZJazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2018 and provided financial...
DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the full year and the fourth quarter of 2018 and provided financial guidance for 2019. "Our evolution as a global biopharmaceutical company continued in 2018 as
Read more →JAZZJazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Anne O'Riordan, Senior Managing Director, Life Sciences of Accenture, was appointed to...
DUBLIN , Feb. 14, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that Anne O'Riordan , Senior Managing Director, Life Sciences of Accenture, was appointed to its Board of Directors, effective February 14, 2019 . The appointment increases the size of
Read more →JAZZJazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 fourth quarter and full year financial results on Tuesday,...
DUBLIN , Feb. 12, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019 , after the close of the financial markets. Company management will host a liv
Read more →JAZZJazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Codiak BioSciences, Inc. today announced that the companies have entered into a strategic collaboration...
Under the terms of the agreement, Codiak is responsible for the execution of pre-clinical and early clinical development of therapeutic candidates directed at all five targets through Phase 1/2 proof of concept studies. Following the conclusion of the applicable Phase 1/2 study,
Read more →JAZZJazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea DUBLIN
Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea DUBLIN, December 21, 2018 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration
Read more →JAZZJazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 7 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 37th Annual J.P. Morgan ...
DUBLIN , Dec. 19, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Bruce Cozadd , chairman and chief executive
Read more →JAZZJazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its Board of Directors has authorized a $400 million increase in the company's share...
DUBLIN , Dec. 10, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that its Board of Directors has authorized a $400 million increase in the company's share repurchase program, which the company intends to use over time based on market conditions and
Read more →JAZZJazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical trial evaluating the efficacy...
DUBLIN , Nov. 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patient has been enrolled in a Phase 3 clinical trial evaluating the efficacy and safety of JZP-258 for the treatment of idiopathic hypersomnia, a sleep disorder charact
Read more →JAZZJazz Pharmaceuticals to Highlight Hematology Research at ASH 2018 Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that nine abstracts, including two oral presentations, relating to the company's...
DUBLIN , Nov. 28, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that nine abstracts, including two oral presentations, relating to the company's hematology/oncology portfolio were accepted for the 60 th American Society of Hematology (ASH) Annual M
Read more →JAZZJazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines...
DUBLIN , Nov. 9, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor, as a treatme
Read more →JAZZNational Institute for Health and Care Excellence (NICE) Recommends Jazz Pharmaceuticals' Vyxeos® (Daunorubicin and Cytarabine) for Adults with Specific Types of Secondary Acute Myeloid Leukaemia (AML) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Institute for Health and Care Excellence (NICE) has published a Final...
DUBLIN , Nov. 7, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending Vyxeos ® 44 mg/100 mg powder for concentrate for solut
Read more →JAZZJazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at four upcoming investor...
DUBLIN , Nov. 7, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentations at four upcoming investor conferences. A live audio webcast of each presentation may be accessed from the Investors sect
Read more →JAZZJazz Pharmaceuticals Announces Third Quarter 2018 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2018 and updated financial guidance for 2018. We...
DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the third quarter of 2018 and updated financial guidance for 2018. "We delivered strong top-line and bottom-line growth in the third quarter and recently achieved
Read more →JAZZJazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug...
DUBLIN , Oct. 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) on October 26, 2018 , to revise labeling for Xyrem ® (sodium oxybate) oral soluti
Read more →JAZZJazz Pharmaceuticals to Report 2018 Third Quarter Financial Results on November 6, 2018 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 third quarter financial results on Tuesday, November 6, 2018,...
DUBLIN , Oct. 23, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2018 third quarter financial results on Tuesday, November 6, 2018 , after the close of the financial markets. Company management will host a live audio webcast
Read more →JAZZJazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to provide investors with an overview of the AML...
DUBLIN , Sept. 11, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will host a webcast to provide investors with an overview of the AML treatment landscape in the EU as well as a Vyxeos EU launch overview from the company's executive
Read more →JAZZVyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission approved Vyxeos® 44 mg/100 mg powder for concentrate for...
DUBLIN , Aug. 27, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the European Commission approved Vyxeos ® 44 mg/100 mg powder for concentrate for solution for infusion for the treatment of adults with newly diagnosed, therapy-related acute mye
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2018 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2018 and updated financial guidance for 2018. We ...
DUBLIN , Aug. 7, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the second quarter of 2018 and updated financial guidance for 2018. "We had another highly productive quarter, including strong commercial performance, achievemen
Read more →JAZZJazz Pharmaceuticals and MD Anderson Cancer Center Collaborate to Evaluate Potential Treatment Options for Hematologic Malignancies Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year collaboration agreement...
DUBLIN and HOUSTON , Aug. 6, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) and The University of Texas MD Anderson Cancer Center today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, includin
Read more →JAZZCMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States Centers for Medicare and Medicaid Services (CMS) granted approval for...
DUBLIN , Aug. 3, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the United States Centers for Medicare and Medicaid Services (CMS) granted approval for a New Technology Add-on Payment (NTAP) for Vyxeos® (daunorubicin and cytarabine) liposome fo
Read more →JAZZJazz Pharmaceuticals to Report 2018 Second Quarter Financial Results on August 7, 2018 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 second quarter financial results on Tuesday, August 7, 2018,...
DUBLIN , July 24, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2018 second quarter financial results on Tuesday, August 7, 2018 , after the close of the financial markets. Company management will host a live audio webcast i
Read more →JAZZJournal of Clinical Oncology publishes pivotal Phase 3 data for Jazz Pharmaceuticals' Vyxeos® (daunorubicin and cytarabine) Liposome for Injection Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that data from the pivotal Phase 3 study of Vyxeos® (daunorubicin and cytarabine) liposome...
DUBLIN , July 19, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that data from the pivotal Phase 3 study of Vyxeos® (daunorubicin and cytarabine) liposome for injection compared to standard of care cytarabine and daunorubicin (7+3) were published o
Read more →JAZZJazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a definitive agreement to sell its rights related to Prialt® (ziconotide) intrathecal...
DUBLIN , June 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced a definitive agreement to sell its rights related to Prialt® (ziconotide) intrathecal infusion to TerSera Therapeutics LLC (TerSera) for $80 million in cash at closing. The transaction
Read more →JAZZVyxeos™ Receives Positive CHMP Opinion for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)...
DUBLIN , June 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorisation of Vyxeos™ 44 mg/100 mg powder
Read more →JAZZJazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review its...
"There has been a great deal of interest from the narcolepsy community in understanding the safety and efficacy of Xyrem in pediatric patients. We look forward to the FDA review and the potential for a new Xyrem indication specific to cataplexy and EDS in children and adolescents
Read more →JAZZJazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its investigational treatment solriamfetol demonstrated long-term maintenance of...
DUBLIN , June 3, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that its investigational treatment solriamfetol demonstrated long-term maintenance of efficacy and a tolerable safety profile in the open-label Phase 3 TONES 5 study of excessive sleepi
Read more →JAZZNew Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced findings from a new survey of the opinions of specialist physicians who treat patients with...
DUBLIN , May 31, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced findings from a new survey of the opinions of specialist physicians who treat patients with obstructive sleep apnea (OSA), a chronic sleep condition often characterized by Excessive Sle
Read more →JAZZJazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to discuss data to be presented on solriamfetol...
DUBLIN , May 24, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will host a webcast to discuss data to be presented on solriamfetol (JZP-110) and Xyrem® (sodium oxybate) oral solution at the Annual Meeting of the Associated Professi
Read more →JAZZJazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that it will present 20 abstracts spanning the company's sleep portfolio at the 32nd Annual...
DUBLIN , May 10, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that it will present 20 abstracts spanning the company's sleep portfolio at the 32nd Annual Meeting of the Associated Professional Sleep Societies, known as "SLEEP", in Baltimore from J
Read more →JAZZJazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at three upcoming investor...
DUBLIN , May 9, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentations at three upcoming investor conferences. A live audio webcast of each presentation may be accessed from the Investors sect
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2018 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2018 and updated financial guidance for 2018. The ...
DUBLIN , May 8, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the first quarter of 2018 and updated financial guidance for 2018. "The first quarter was highlighted by strong revenue growth, cash flow generation and execution
Read more →JAZZJazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has filed a supplemental new drug application (sNDA) with the U.S. Food and Drug...
DUBLIN , May 1, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it has filed a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) on April 27, 2018 seeking revised labeling for Xyrem® (sodium oxybate) oral
Read more →JAZZJazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 first quarter financial results on Tuesday, May 8, 2018, after...
DUBLIN , April 24, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2018 first quarter financial results on Tuesday, May 8, 2018 , after the close of the financial markets. Company management will host a live audio webcast imme
Read more →JAZZJazz Pharmaceuticals Announces Participation in Two Investor Conferences in March Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...
DUBLIN , March 6, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. A live audio webcast of each presentation may be accessed from the Investors sect
Read more →JAZZJazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2017 and provided financial...
DUBLIN , Feb. 27, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the full year and the fourth quarter of 2017 and provided financial guidance for 2018. "2017 was a pivotal year for Jazz as we delivered record revenues while ac
Read more →JAZZJazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the efficacy...
DUBLIN , Feb. 23, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the efficacy and safety of defibrotide for the prevention of acute Graft-versus-Host-Disease (aGvHD) in
Read more →JAZZJazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 fourth quarter and full year financial results on Tuesday,...
DUBLIN , Feb. 13, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018 , after the close of the financial markets. Company management will host a liv
Read more →JAZZNational Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network® (NCCN®) added Vyxeos™ (daunorubicin and...
DUBLIN , Feb. 8, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the National Comprehensive Cancer Network ® (NCCN ® ) added Vyxeos™ (daunorubicin and cytarabine) liposome for injection to the Clinical Practice Guidelines in Oncology (NCCN Guide
Read more →JAZZJazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 8 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 36th Annual J.P. Morgan ...
DUBLIN , Jan. 2, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco , CA. Bruce Cozadd , chairman and chief executive o
Read more →JAZZJazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on...
DUBLIN , Dec. 21, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on December 20, 2017 seeking marketing approval for solriamfetol (JZP-110), an investigational m
Read more →JAZZJazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the BMO Capital Markets...
DUBLIN , Dec. 7, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the BMO Capital Markets Healthcare Conference in New York , NY. Matt Young , executive vice president and chief financ
Read more →JAZZJazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Daniel N. Swisher, Jr. as president and chief operating officer, effective ...
DUBLIN , Dec. 4, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the appointment of Daniel N. Swisher, Jr. as president and chief operating officer, effective January 3 , 2018. Mr. Swisher will report to Bruce Cozadd , chairman and chief executive of
Read more →JAZZJazz Pharmaceuticals Announces Third Quarter 2017 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2017 and updated financial guidance for 2017. The ...
DUBLIN , Nov. 7, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the third quarter of 2017 and updated financial guidance for 2017. "The third quarter of 2017 was highlighted by the approval and strong launch of Vyxeos in the U
Read more →JAZZJazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines...
DUBLIN , Nov. 3, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Vyxeos™ (daunorubicin and cyta
Read more →JAZZJazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that thirteen abstracts spanning the company's hematology/oncology portfolio will be...
DUBLIN , Nov. 1, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that thirteen abstracts spanning the company's hematology/oncology portfolio will be presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta from December 9
Read more →JAZZJazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 third quarter financial results on Tuesday, November 7, 2017,...
DUBLIN , Oct. 24, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2017 third quarter financial results on Tuesday, November 7, 2017 , after the close of the financial markets. Company management will host a live audio webcast
Read more →JAZZFortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company was named to Fortune magazine's list of fastest growing companies for 2017....
DUBLIN , Sept. 12, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company was named to Fortune magazine's list of fastest growing companies for 2017. In Fortune's annual rankings, Jazz was named the 78 th fastest growing company . "We are
Read more →JAZZJazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024 DUBLIN
Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024 DUBLIN, September 1, 2017 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ( Jazz Pharmaceuticals ) today announced th
Read more →JAZZJazz Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Wells Fargo Securities...
DUBLIN , Aug. 30, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the Wells Fargo Securities Healthcare Conference in Boston , MA. Bruce Cozadd , chairman and chief executive officer,
Read more →JAZZJazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and ImmunoGen, Inc. (Nasdaq: IMGN) today announced that the companies have entered into a collaboration and...
DUBLIN and WALTHAM, Mass. , Aug. 29, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) and ImmunoGen, Inc. (Nasdaq: IMGN ) today announced that the companies have entered into a collaboration and option agreement granting Jazz Pharmaceuticals exclusive, worldwide righ
Read more →JAZZJazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024 DUBLIN
Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024 DUBLIN, Aug. 17, 2017 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an offering by Jazz Investments I Limited, its wholly-owned subsidiary (the Issuer ), of $500 million aggr
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2017 Financial Results Received FDA Approval of Vyxeos for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with...
DUBLIN , Aug. 8, 2017 /PRNewswire/ -- Received FDA Approval of Vyxeos for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC) in the U.S. Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today
Read more →JAZZJazz Pharmaceuticals Announces FDA Approval of Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has approved Vyxeos™ (daunorubicin and...
DUBLIN , Aug. 3, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the U.S. Food and Drug Administration (FDA) has approved Vyxeos™ (daunorubicin and cytarabine) liposome for injection for the treatment of adults with two types of Acute Myeloid Le
Read more →JAZZJazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, August 7, 2017 at 4:30 p.m. EDT/9:30 p.m. IST ...
DUBLIN , Aug. 3, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will host a webcast on Monday, August 7, 2017 at 4:30 p.m. EDT / 9:30 p.m. IST to provide investors with an update on Vyxeos™ (daunorubicin and cytarabine) liposome for
Read more →JAZZJazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a license agreement with XL-protein GmbH ( XLp ) for the rights to...
DUBLIN , July 26, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it has entered into a license agreement with XL-protein GmbH ("XLp") for the rights to develop, manufacture and commercialize products using XLp's PASylation ® Technology to exten
Read more →JAZZJazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 second quarter financial results on Tuesday, August 8, 2017,...
DUBLIN , July 24, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2017 second quarter financial results on Tuesday, August 8, 2017 , after the close of the financial markets. Company management will host a live audio webcast i
Read more →JAZZJazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented the positive efficacy results from its global multicenter study of JZP-110 in adult patients...
DUBLIN , June 6, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today presented the positive efficacy results from its global multicenter study of JZP-110 in adult patients with excessive sleepiness associated with narcolepsy. The data were presented today in a pos
Read more →JAZZJazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented positive efficacy results from its global multicenter studies (TONES 3 and TONES 4) of...
DUBLIN , June 6, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today presented positive efficacy results from its global multicenter studies (TONES 3 and TONES 4) of JZP-110 in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA).
Read more →JAZZJazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review ...
DUBLIN , May 31, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for VYXEOS™ (cytarabine and daunorubicin)
Read more →JAZZJazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that twelve abstracts supporting the company's sleep medicine portfolio, including data on...
DUBLIN, Ireland, May 24, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that twelve abstracts supporting the company's sleep medicine portfolio, including data on its investigational compound JZP-110, data on the investigational use of sodium oxybat
Read more →JAZZJazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to discuss data to be presented on JZP-110 and Xyrem®...
DUBLIN , May 24, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will host a webcast to discuss data to be presented on JZP-110 and Xyrem® (sodium oxybate) oral solution during the Associated Professional Sleep Societies (APSS) Annua
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2017 Financial Results Total Revenues Increased 12% to $376 Million Settled Xyrem Patent Litigation with First ANDA Filer Completed Rolling NDA Submission for Vyxeos...
DUBLIN , May 9, 2017 /PRNewswire/ -- Total Revenues Increased 12% to $376 Million Settled Xyrem Patent Litigation with First ANDA Filer Completed Rolling NDA Submission for Vyxeos (CPX-351) Announced Positive Top-Line Data for JZP-110 in Obstructive Sleep Apnea and Narcolepsy
Read more →JAZZJazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy results from the global multicenter study of JZP-110 in adult patients with ...
DUBLIN , April 26, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced positive efficacy results from the global multicenter study of JZP-110 in adult patients with excessive sleepiness associated with narcolepsy. Based on the preliminary safety analysis
Read more →JAZZJazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 first quarter financial results on Tuesday, May 9, 2017, after...
DUBLIN , April 25, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2017 first quarter financial results on Tuesday, May 9, 2017 , after the close of the financial markets. Company management will host a live audio webcast imme
Read more →JAZZJazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line efficacy results from the global, double-blind, placebo-controlled,...
DUBLIN , April 24, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced positive top-line efficacy results from the global, double-blind, placebo-controlled, randomized-withdrawal, multicenter Phase 2/3 study evaluating Xyrem® (sodium oxybate) oral soluti
Read more →JAZZJazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigation Hikma Granted Right to Sell Authorized Generic of Xyrem in 2023 DUBLIN
Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigation Hikma Granted Right to Sell Authorized Generic of Xyrem in 2023 DUBLIN, April 5, 2017 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that certain of its subsidiaries
Read more →JAZZJazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion on March 31, 2017 of a rolling submission of a New Drug Application (NDA) to...
DUBLIN , April 3, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the completion on March 31, 2017 of a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of Vyxeos™ (cytarabine and daun
Read more →JAZZJazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Commercialization of Defitelio and Vyxeos in Japan Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into license agreements with Nippon Shinyaku, Co., Ltd. for Defitelio®...
DUBLIN , March 30, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it has entered into license agreements with Nippon Shinyaku, Co., Ltd. for Defitelio ® (defibrotide sodium) and Vyxeos ™ (cytarabine and daunorubicin liposome injection), or CPX-
Read more →JAZZJazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy results from two global multicenter studies in adult patients with...
DUBLIN , March 20, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced positive efficacy results from two global multicenter studies in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA). JZP-110 demonstrated highly st
Read more →JAZZJazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical study evaluating JZP-258, an...
DUBLIN , March 15, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patient has been enrolled in a Phase 3 clinical study evaluating JZP-258, an investigational oxybate product candidate with 90 percent less sodium content than Xyrem® (
Read more →JAZZJazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2016 and provided financial...
DUBLIN , Feb. 28, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the full year and the fourth quarter of 2016 and provided financial guidance for 2017. "In 2016, we delivered solid growth for two of our key products, Xyrem and
Read more →JAZZJazz Pharmaceuticals to Report 2016 Fourth Quarter and Full Year Financial Results on February 28, 2017 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2016 fourth quarter and full year financial results on Tuesday,...
DUBLIN , Feb. 14, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2016 fourth quarter and full year financial results on Tuesday, February 28, 2017 , after the close of the financial markets. Company management will host a liv
Read more →JAZZJazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson's Disease Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical study evaluating JZP-110, a...
DUBLIN , Feb. 8, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patient has been enrolled in a Phase 2 clinical study evaluating JZP-110, a selective dopamine and norepinephrine reuptake inhibitor, as a potential treatment for excessi
Read more →JAZZJazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical trial comparing the efficacy...
DUBLIN , Jan. 17, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patient has been enrolled in a Phase 3 clinical trial comparing the efficacy and safety of defibrotide versus best supportive care (BSC) in the prevention of hepatic ven
Read more →JAZZJazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 9 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 35th Annual J.P. Morgan ...
DUBLIN , Jan. 3, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Bruce Cozadd , chairman and chief executive of
Read more →JAZZJazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that patient enrollment has been completed in its Phase 3 study evaluating JZP-110 in...
DUBLIN , Nov. 28, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that patient enrollment has been completed in its Phase 3 study evaluating JZP-110 in excessive sleepiness (ES) associated with narcolepsy. "This is an important milestone in our JZP-
Read more →JAZZJazz Pharmaceuticals to Present New Data at the Annual ASH Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that eleven abstracts, including four oral presentations, supporting the company's hematology ...
DUBLIN , Nov. 7, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that eleven abstracts, including four oral presentations, supporting the company's hematology and oncology portfolio will be presented at the 58th American Society of Hematology (ASH) A
Read more →JAZZJazz Pharmaceuticals to Report 2016 Third Quarter Financial Results on November 8, 2016 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2016 third quarter financial results on Tuesday, November 8, 2016,...
DUBLIN , Oct. 25, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2016 third quarter financial results on Tuesday, November 8, 2016 , after the close of the financial markets. Company management will host a live audio webcast
Read more →JAZZJazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission by Early 2017 Jazz Pharmaceuticals plc (Nasdaq; JAZZ) today announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States...
DUBLIN , Oct. 3, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq; JAZZ) today announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) on September 30, 2016 , seeking marketing approval o
Read more →JAZZJazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that patient enrollment has been completed for its two Phase 3 studies evaluating JZP-110 in...
DUBLIN , Sept. 26, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that patient enrollment has been completed for its two Phase 3 studies evaluating JZP-110 in excessive sleepiness (ES) associated with obstructive sleep apnea (OSA). "We are pleased
Read more →JAZZJazz Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Morgan Stanley Global...
DUBLIN , Sept. 7, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the Morgan Stanley Global Healthcare Conference in New York, NY . Bruce C. Cozadd , chairman and chief executive offi
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2016 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2016 and updated financial guidance for 2016. We ...
DUBLIN , Aug. 9, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the second quarter of 2016 and updated financial guidance for 2016. "We have made significant progress in 2016, as we continue to build the foundation for future
Read more →JAZZCMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States (U.S.) Centers for Medicare and Medicaid Services (CMS) has granted a...
DUBLIN , Aug. 2, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the United States (U.S.) Centers for Medicare and Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for Defitelio® (defibrotide sodium), which is indicated
Read more →JAZZJazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Pfenex Inc. (NYSE MKT: PFNX) today announced an agreement under which Pfenex granted Jazz Pharmaceuticals ...
DUBLIN and SAN DIEGO , July 28, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) and Pfenex Inc. (NYSE MKT: PFNX) today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematolog
Read more →JAZZJazz Pharmaceuticals to Report 2016 Second Quarter Financial Results on August 9, 2016 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2016 second quarter financial results on Tuesday, August 9, 2016,...
DUBLIN , July 25, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2016 second quarter financial results on Tuesday, August 9, 2016 , after the close of the financial markets. Company management will host a live audio webcast i
Read more →JAZZJazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares of Common Stock of Celator Pharmaceuticals, Inc. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the results of its tender offer to purchase all of the outstanding shares of common stock of...
DUBLIN , July 12, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Celator Pharmaceuticals, Inc. (NASDAQ: CPXX ) at $30.25 per share, net to the seller in cas
Read more →JAZZJazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals, Inc. Acquisition Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended...
DUBLIN , June 27, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), with respect to its proposed acquisition of Celator Pharmaceuticals, Inc. ("Celato
Read more →JAZZJazz Pharmaceuticals Announces Conference Call and Webcast for JZP-110 Investor Update Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it is hosting an investor conference call and audio webcast on Monday, June 20, 2016 at...
DUBLIN , June 14, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it is hosting an investor conference call and audio webcast on Monday, June 20, 2016 at 4:30 p.m. EDT / 9:30 p.m. IST to provide investors with an update on JZP-110, including a d
Read more →JAZZJazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that they have entered into a definitive...
DUBLIN and EWING, N.J. , May 31, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) and Celator Pharmaceuticals, Inc. (Nasdaq: CPXX ) today announced that they have entered into a definitive agreement for Jazz Pharmaceuticals to acquire Celator for $30.25 per share in
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2016 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2016 and updated financial guidance for 2016....
DUBLIN , May 10, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the first quarter of 2016 and updated financial guidance for 2016. "During the first quarter of 2016, we executed on our business model by delivering strong top-
Read more →JAZZJazz Pharmaceuticals to Report 2016 First Quarter Financial Results on May 10, 2016 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2016 first quarter financial results on Tuesday, May 10, 2016, after...
DUBLIN , April 26, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2016 first quarter financial results on Tuesday, May 10, 2016 , after the close of the financial markets. Company management will host a live audio webcast imm
Read more →JAZZJazz Pharmaceuticals Announces Webcast for Defitelio® (defibrotide sodium) Investor Update Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Thursday, March 31, 2016 at 4:30 p.m. EDT/9:30 p.m....
DUBLIN , March 30, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will host a webcast on Thursday, March 31, 2016 at 4:30 p.m. EDT / 9:30 p.m. IST to provide investors with an update on Defitelio, which was approved by the U.S. Food
Read more →JAZZJazz Pharmaceuticals Announces FDA Approval of Defitelio® (defibrotide sodium) for the Treatment of Hepatic Veno-Occlusive Disease (VOD) with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation (HSCT) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States (U.S.) Food and Drug Administration (FDA) granted marketing approval...
DUBLIN , March 30, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the United States (U.S.) Food and Drug Administration (FDA) granted marketing approval for Defitelio ® (defibrotide sodium) for the treatment of adult and pediatric patients with
Read more →JAZZJazz Pharmaceuticals Announces Full Year And Fourth Quarter 2015 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2015 and provided financial...
DUBLIN , Feb. 23, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the full year and the fourth quarter of 2015 and provided financial guidance for 2016. "In 2015, we delivered solid growth on the top- and bottom-line while incr
Read more →JAZZJazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that researchers will present three Jazz-sponsored oral abstracts related to the ongoing...
DUBLIN , Feb. 18, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that researchers will present three Jazz-sponsored oral abstracts related to the ongoing evaluation of defibrotide, an investigational medicine being studied in the United States (U.S.
Read more →JAZZJazz Pharmaceuticals to Report 2015 Fourth Quarter and Full Year Financial Results on February 23, 2016 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2015 fourth quarter and full year financial results on Tuesday,...
DUBLIN , Feb. 9, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2015 fourth quarter and full year financial results on Tuesday, February 23, 2016 , after the close of the financial markets. Company management will host a live
Read more →JAZZResults from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that data from the phase 3 pivotal study of defibrotide were published online in BLOOD, the...
DUBLIN , Feb. 1, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that data from the phase 3 pivotal study of defibrotide were published online in BLOOD , the Journal of the American Society of Hematology (ASH). The data demonstrated that defibrotide
Read more →JAZZJazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 11 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 34th Annual J.P. Morgan ...
DUBLIN , Jan. 4, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the 34 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Bruce C. Cozadd , chairman and chief executiv
Read more →JAZZJazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at three upcoming investor...
DUBLIN , Nov. 4, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at three upcoming investor conferences. A live audio webcast of each presentation may be accessed from the Investors & Me
Read more →JAZZJazz Pharmaceuticals to Report 2015 Third Quarter Financial Results on November 9, 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2015 third quarter financial results on Monday, November 9, 2015,...
DUBLIN , Oct. 26, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2015 third quarter financial results on Monday, November 9, 2015 , after the close of the financial markets. Company management will host a live audio webcast i
Read more →JAZZJazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted for filing with ...
DUBLIN , Sept. 30, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for defibrotide. Defibr
Read more →JAZZJazz Pharmaceuticals to Report 2015 Second Quarter Financial Results on August 5, 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2015 second quarter financial results on Wednesday, August 5, 2015,...
DUBLIN , July 22, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2015 second quarter financial results on Wednesday, August 5, 2015 , after the close of the financial markets. Company management will host a live audio webcast
Read more →JAZZJazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Cantor Fitzgerald...
DUBLIN , July 1, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the Cantor Fitzgerald Healthcare Conference in New York , NY. Russell Cox , executive vice president and chief operati
Read more →JAZZJazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy or with Obstructive Sleep Apnea (OSA) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the first patients have been enrolled in a Phase 3 clinical development program...
DUBLIN , June 8, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that the first patients have been enrolled in a Phase 3 clinical development program evaluating the safety and efficacy of its investigational drug candidate, JZP-110, as a wake-promoti
Read more →JAZZJazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem® (sodium oxybate) at SLEEP 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will present abstracts related to the ongoing clinical evaluation of Xyrem® (sodium oxybate) oral solution, a ...
DUBLIN , June 4, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) will present abstracts related to the ongoing clinical evaluation of Xyrem® (sodium oxybate) oral solution, a U.S. Food and Drug Administration (FDA) approved treatment for both excessive daytime sleep
Read more →JAZZJazz Pharmaceuticals Announces Participation in Two Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...
DUBLIN , May 15, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. A live audio webcast of each presentation may be accessed from the Investors & Med
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2015 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter ended March 31, 2015 and reaffirmed financial...
DUBLIN , May 7, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the first quarter ended March 31, 2015 and reaffirmed financial guidance for 2015. "We are pleased with our strong top-line performance during the first quarter, d
Read more →JAZZJazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2015 first quarter financial results on Thursday, May 7, 2015, after...
DUBLIN , April 23, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2015 first quarter financial results on Thursday, May 7, 2015 , after the close of the financial markets. Company management will host a live audio webcast imm
Read more →JAZZJazz Pharmaceuticals Announces Full Year And Fourth Quarter 2014 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter ended December 31, 2014 and...
DUBLIN , Feb. 24, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the full year and the fourth quarter ended December 31, 2014 and provided financial guidance for 2015. "2014 was an outstanding year for Jazz Pharmaceuticals as
Read more →JAZZJazz Pharmaceuticals to Present Data on Defibrotide, an Investigational Treatment, in Patients with Hepatic Veno-Occlusive Disease (VOD) at BMT Tandem Meetings Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that researchers will present data on the use of defibrotide, an investigational medicine...
DUBLIN , Feb. 12, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease
Read more →JAZZJazz Pharmaceuticals to Report 2014 Fourth Quarter and Full Year Financial Results on February 24, 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 fourth quarter and full year financial results on Tuesday,...
DUBLIN , Feb. 10, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2014 fourth quarter and full year financial results on Tuesday, February 24, 2015 , after the close of the financial markets. Company management will host a liv
Read more →JAZZJazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 12 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 33rd Annual J.P. Morgan ...
DUBLIN , Jan. 5, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the 33 rd Annual J.P. Morgan Healthcare Conference in San Francisco , CA. Bruce C. Cozadd , chairman and chief executi
Read more →JAZZJazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze® (asparaginase Erwinia chrysanthemi) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous administration of...
DUBLIN , Dec. 19, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi ). Erwinaze is indicated as a component of a mu
Read more →JAZZJazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States...
DUBLIN , Dec. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for defibrotide for the treatment of severe hepati
Read more →JAZZJazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem® (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patients have been enrolled in a Phase 3 clinical trial to assess the safety...
DUBLIN , Dec. 2, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patients have been enrolled in a Phase 3 clinical trial to assess the safety and efficacy of Xyrem® (sodium oxybate) in children and adolescents aged seven to 17 who have
Read more →JAZZJazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease (VOD) At ASH Annual Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that researchers will present the results of a number needed to treat (NNT; an...
DUBLIN , Dec. 2, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that researchers will present the results of a number needed to treat (NNT; an epidemiological measure of effectiveness) analysis from a historically controlled Phase 3 clinical trial e
Read more →JAZZJazz Pharmaceuticals Announces Third Quarter 2014 Financial Results And Updated Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter ended September 30, 2014 and updated financial...
DUBLIN , Nov. 4, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the third quarter ended September 30, 2014 and updated financial guidance for full year 2014. "We successfully executed on key goals across the business, from str
Read more →JAZZJazz Pharmaceuticals to Report 2014 Third Quarter Financial Results on November 4, 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 third quarter financial results on Tuesday, November 4, 2014,...
DUBLIN , Oct. 21, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2014 third quarter financial results on Tuesday, November 4, 2014 , after the close of the financial markets. Company management will host a live audio webcast
Read more →JAZZJazz Pharmaceuticals Announces Pricing of $500 Million of Exchangeable Senior Notes Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the Issuer ), priced its...
DUBLIN , Aug. 8, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), priced its previously announced offering of $500 million aggregate principal amount of exchangeable senior n
Read more →JAZZJazz Pharmaceuticals Announces Proposed Offering of $500 Million of Exchangeable Senior Notes Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the Issuer ), intends to...
DUBLIN , Aug. 6, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2014 Financial Results And Updated Guidance Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter ended June 30, 2014 and updated financial guidance...
DUBLIN , Aug. 5, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the second quarter ended June 30, 2014 and updated financial guidance for 2014. "Strong underlying demand for our products and the start of our European Union lau
Read more →JAZZJazz Pharmaceuticals Completes Acquisition Of Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of its acquisition of rights to defibrotide in the United States (U.S.) and all...
DUBLIN , Aug. 5, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the closing of its acquisition of rights to defibrotide in the United States (U.S.) and all other countries in the Americas from Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau). Jazz Pharma
Read more →JAZZJazz Pharmaceuticals Announces Participation at Canaccord Genuity Conference on August 13 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Canaccord Genuity 34th...
DUBLIN , Aug. 4, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the Canaccord Genuity 34 th Annual Growth Conference in Boston, MA on Wednesday, August 13, 2014 at 9:00 a.m. EDT / 2:0
Read more →JAZZJazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014,...
DUBLIN , July 22, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014 , after the close of the financial markets. Company management will host a live audio webcast i
Read more →JAZZJazz Pharmaceuticals Announces Agreement To Acquire Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals, Inc....
DUBLIN , July 2, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) under which a subsidiary of Jazz Pharmaceuticals plc (Jazz) will acquire from Sigma-T
Read more →JAZZJazz Pharmaceuticals Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented data from the Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential...
DUBLIN , June 2, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today presented data from the Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential new treatment for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy
Read more →JAZZJazz Pharmaceuticals To Present Data On Compound In Sleep Pipeline During APSS Annual SLEEP Meeting Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that new data for the investigational compound JZP-110 (previously ADX-N05) will be presented ...
DUBLIN , May 27, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that new data for the investigational compound JZP-110 (previously ADX-N05) will be presented at the 28th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, May 31 to
Read more →JAZZJazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Russell J. Cox to the newly created position of chief operating officer...
DUBLIN , May 19, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO). Mr. Cox, who joined Jazz Pharmaceuticals in July 2010 , most recently served as executi
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2014 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter ended March 31, 2014 and reaffirmed and updated...
DUBLIN , May 8, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the first quarter ended March 31, 2014 and reaffirmed and updated financial guidance for 2014. "We are pleased with the progress made during the first quarter, hig
Read more →JAZZJazz Pharmaceuticals to Report 2014 First Quarter Financial Results on May 8, 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 first quarter financial results on Thursday, May 8, 2014, after...
DUBLIN , April 24, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2014 first quarter financial results on Thursday, May 8, 2014 , after the close of the financial markets. Company management will host a live audio webcast imm
Read more →JAZZJazz Pharmaceuticals Announces Management Change Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Kathryn Falberg, executive vice president and chief financial officer (CFO), has...
DUBLIN , Feb. 25, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that Kathryn Falberg , executive vice president and chief financial officer (CFO), has resigned from the company, effective March 9, 2014, to pursue other interests. Ms. Falberg will s
Read more →JAZZJazz Pharmaceuticals Announces Full Year And Fourth Quarter 2013 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter ended December 31, 2013 and...
DUBLIN , Feb. 25, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the full year and the fourth quarter ended December 31, 2013 and provided financial guidance for 2014. "2013 was an outstanding year as we delivered strong top-l
Read more →JAZZJazz Pharmaceuticals plc Completes Tender Offer For Gentium S.p.A. Shares Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the subsequent offering period of the tender offer made by a subsidiary of Jazz...
DUBLIN , Feb. 21, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the subsequent offering period of the tender offer made by a subsidiary of Jazz Pharmaceuticals to purchase all outstanding ordinary shares and American Depositary Shares ("ADSs")
Read more →JAZZJazz Pharmaceuticals to Report 2013 Fourth Quarter and Full Year Financial Results on February 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2013 fourth quarter and full year financial results on Tuesday,...
DUBLIN , Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2013 fourth quarter and full year financial results on Tuesday, February 25, 2014 , after the close of the financial markets. Company management will host a liv
Read more →JAZZJazz Pharmaceuticals Announces U.S. Commercial Availability Of Versacloz™ (clozapine, USP) Oral Suspension Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability of Versacloz™ (clozapine, USP) oral suspension, the first and...
DUBLIN , Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced U.S. commercial availability of Versacloz™ (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or
Read more →JAZZJazz Pharmaceuticals Breaks Ground On New Manufacturing And Development Facility In Ireland azz Pharmaceuticals (Nasdaq: JAZZ) today announced that it has commenced construction of a manufacturing and development facility to be located on a...
DUBLIN , Feb. 10, 2014 /PRNewswire/ --Jazz Pharmaceuticals (Nasdaq: JAZZ ) today announced that it has commenced construction of a manufacturing and development facility to be located on a 17-acre site in Monksland, County Roscommon , approximately 75 miles east of the company's
Read more →JAZZJazz Pharmaceuticals plc Announces Minimum Tender Condition Exceeded During Initial Offering Period For Gentium S.p.A. Shares Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the initial offering period in the tender offer made by a subsidiary of Jazz...
DUBLIN , Jan. 23, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the initial offering period in the tender offer made by a subsidiary of Jazz Pharmaceuticals to purchase all outstanding ordinary shares and American Depositary Shares ("ADSs") of
Read more →JAZZJazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Aerial BioPharma, LLC (Aerial) today announced that the companies have signed a definitive agreement...
DUBLIN , Jan. 13, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) and Aerial BioPharma, LLC (Aerial) today announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical d
Read more →JAZZJazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 32nd Annual J.P. Morgan ...
DUBLIN , Jan. 6, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the 32 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Bruce C. Cozadd , chairman and chief executiv
Read more →JAZZJazz Pharmaceuticals And Gentium S.p.A. Announce Agreement For Jazz Pharmaceuticals To Acquire Gentium For $57.00 Per Share Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A. (Nasdaq: GENT) today announced that they have entered into a definitive agreement pursuant ...
DUBLIN , Ireland and VILLA GUARDIA, Italy , Dec. 19, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) and Gentium S.p.A. (Nasdaq: GENT ) today announced that they have entered into a definitive agreement pursuant to which a subsidiary of Jazz Pharmaceuticals will mak
Read more →JAZZJazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its participation at the 25th Annual Piper Jaffray...
DUBLIN , Nov. 20, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its participation at the 25th Annual Piper Jaffray Healthcare Conference in New York, NY . Bruce C. Cozadd , chairman and chief executive officer,
Read more →JAZZJazz Pharmaceuticals Announces Third Quarter 2013 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter ended September 30, 2013 and updated 2013 financial...
DUBLIN , Nov. 5, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the third quarter ended September 30, 2013 and updated 2013 financial guidance. "We continued to deliver strong growth and profitability during the third quarter
Read more →JAZZJazz Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference on November 12 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 2013 Credit Suisse...
DUBLIN , Nov. 1, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will be webcasting its corporate presentation at the 2013 Credit Suisse Healthcare Conference in Phoenix, AZ. Bruce C. Cozadd , chairman and chief executive officer, w
Read more →JAZZJazz Pharmaceuticals to Report Third Quarter 2013 Financial Results on November 5, 2013 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its third quarter 2013 financial results on Tuesday, November 5, 2013,...
DUBLIN , Oct. 22, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its third quarter 2013 financial results on Tuesday, November 5, 2013 , after the close of the financial markets. Company management will host a live audio webcast
Read more →JAZZJAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2013 FINANCIAL RESULTS Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter ended June 30, 2013 and updated 2013 financial...
DUBLIN , Aug. 6, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the second quarter ended June 30, 2013 and updated 2013 financial guidance. "During the second quarter, we continued our track record of delivering strong top and
Read more →JAZZJazz Pharmaceuticals To Report Second Quarter 2013 Financial Results on August 6, 2013 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its second quarter 2013 financial results on Tuesday, August 6, 2013,...
DUBLIN , July 23, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its second quarter 2013 financial results on Tuesday, August 6, 2013 , after the close of the financial markets. Company management will host a live audio webcast i
Read more →JAZZNew Research at SLEEP 2013 Demonstrates People with Narcolepsy Face Significant Health and Economic Burden and High Rates of Misdiagnosis Researchers will present data today that demonstrate people with narcolepsy face significant personal health and economic burden. The Burden of...
DUBLIN , June 5, 2013 /PRNewswire/ -- Researchers will present data today that demonstrate people with narcolepsy face significant personal health and economic burden. The Burden of Narcolepsy Disease (BOND) study, the largest of its kind and the first in the United States , foun
Read more →JAZZJazz Pharmaceuticals Announces Participation In Upcoming Investor Events Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in three upcoming investor events. A live audio webcast of...
DUBLIN , May 13, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will participate in three upcoming investor events. A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals web
Read more →JAZZJAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter ended March 31, 2013, updated 2013 financial guidance ...
DUBLIN , May 7, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the first quarter ended March 31, 2013 , updated 2013 financial guidance and key additions to its board of directors. "During the first quarter, we continued to de
Read more →JAZZJazz Pharmaceuticals To Report First Quarter 2013 Financial Results On May 7, 2013 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its first quarter 2013 financial results on Tuesday, May 7, 2013, after...
DUBLIN , April 23, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its first quarter 2013 financial results on Tuesday, May 7, 2013 , after the close of the financial markets. The announcement will be followed by a conference call
Read more →JAZZJazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the pricing of a previously announced underwritten public offering of 5,375,000 of its...
DUBLIN , March 5, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the pricing of a previously announced underwritten public offering of 5,375,000 of its ordinary shares held by certain of its existing shareholders, offered at a price to the public of
Read more →JAZZJazz Pharmaceuticals Announces Participation At Two Investor Conferences In March Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will participate in two upcoming investor conferences. A live webcast of...
DUBLIN , Feb. 27, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that the company will participate in two upcoming investor conferences. A live webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals websi
Read more →JAZZJazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter ended December 31, 2012. 2012 was a...
DUBLIN , Feb. 26, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the full year and fourth quarter ended December 31, 2012 . "2012 was a transformational year, with the acquisitions of Azur Pharma and EUSA Pharma expanding our
Read more →JAZZJazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a conference call and live webcast on Tuesday, February 26, 2013 at 4:30...
DUBLIN , Feb. 11, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will host a conference call and live webcast on Tuesday, February 26, 2013 at 4:30 p.m. EST / 9:30 p.m. GMT . During the call, company management will provide a business and fi
Read more →JAZZJazz Pharmaceuticals to Webcast Presentation at J.P. Morgan Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will webcast its presentation at the 31st Annual J.P. Morgan Healthcare...
DUBLIN , Jan. 2, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that the company will webcast its presentation at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2013 . The webcast is scheduled to begin at 1
Read more →JAZZJazz Pharmaceuticals Announces Presentation Of Largest Safety Trial To Date Of Patients Treated With Erwinaze® Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that data from the largest safety trial to date of patients treated with Erwinaze®...
DUBLIN , Dec. 10, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that data from the largest safety trial to date of patients treated with Erwinaze ® (asparaginase Erwinia chrysanthemi ) have been presented at the American Society of Hematology Annua
Read more →JAZZJazz Pharmaceuticals Announces Issuance of Additional Xyrem® Patent Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States Patent and Trademark Office has issued a patent related to the use of...
DUBLIN , Dec. 4, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the United States Patent and Trademark Office has issued a patent related to the use of Xyrem® (sodium oxybate) oral solution for the treatment of narcolepsy, titled "Microbiologic
Read more →JAZZJazz Pharmaceuticals Begins Clinical Trial of Intravenously Administered Erwinaze® In Patients with Acute Lymphoblastic Leukemia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze®...
DUBLIN , Dec. 3, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze ® (asparaginase Erwinia chrysanthemi ) administered intravenously (IV) as an alternative method of adm
Read more →JAZZJazz Pharmaceuticals Announces Participation In Three Investor Conferences In November Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will participate in three upcoming investor conferences. A live webcast of...
DUBLIN , Nov. 9, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that the company will participate in three upcoming investor conferences. A live webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals webs
Read more →JAZZJazz Pharmaceuticals Announces Support for National Campaign Designed to Curb Prescription Drug Abuse Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today its support of The Partnership at Drugfree.org's recently launched national action campaign,...
DUBLIN , Nov. 5, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today its support of The Partnership at Drugfree.org's recently launched national action campaign, The Medicine Abuse Project. The initiative is intended as a multi-year public awareness and
Read more →JAZZJazz Pharmaceuticals Announces Date to Release Third Quarter 2012 Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a conference call and live webcast on Thursday, November 8, 2012 at 4:30...
DUBLIN , Oct. 29, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will host a conference call and live webcast on Thursday, November 8, 2012 at 4:30 p.m. EST / 9:30 p.m. GMT . During the call, company management will provide a business and fi
Read more →JAZZJazz Pharmaceuticals Completes Sale of its Women's Health Business to Meda Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the sale of its women's health business to Meda (an international specialty...
DUBLIN , Oct. 15, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the closing of the sale of its women's health business to Meda (an international specialty pharmaceutical company) for $95 million in cash. The products included in the sale are Elest
Read more →JAZZJazz Pharmaceuticals Enters Definitive Agreement to Sell its Women's Health Business to Meda Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a definitive agreement to sell its women's health business, which includes six products, to...
DUBLIN , Sept. 6, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced a definitive agreement to sell its women's health business, which includes six products, to Meda (an international specialty pharmaceutical company) for $95 million in cash. The produ
Read more →JAZZJazz Pharmaceuticals Announces Participation At The 2012 Morgan Stanley Global Healthcare Conference In New York On September 11 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will participate at the 2012 Morgan Stanley Global Healthcare Conference in...
DUBLIN , Sept. 6, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that the company will participate at the 2012 Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 11, 2012 at 9:45 a.m. EST / 2:45 p.m. GMT . Kate Falberg , e
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2012 Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter ended June 30, 2012. These results include the first ...
DUBLIN , Aug. 7, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced financial results for the second quarter ended June 30 , 2012. These results include the first complete quarter of financial results following the Azur Pharma plc merger, as well as a p
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2012 Financial Results Conference Call On August 7, 2012 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a conference call and live webcast on Tuesday, August 7, 2012 at 4:30 p.m....
DUBLIN , July 31, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will host a conference call and live webcast on Tuesday, August 7, 2012 at 4:30 p.m. EDT / 9:30 p.m. IST . During the call, company management will provide a business and finan
Read more →JAZZCatherine Sohn Elected To Jazz Pharmaceuticals Board Of Directors Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the election of Catherine Angell Sohn, Pharm.D., CLP, to its board of directors at the...
DUBLIN , July 30, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the election of Catherine Angell Sohn , Pharm.D., CLP, to its board of directors at the company's annual meeting of shareholders held on July 27, 2012 . "Cathy has extensive product a
Read more →JAZZJazz Pharmaceuticals Completes EUSA Pharma Acquisition Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of its acquisition of EUSA Pharma, a privately-held, specialty pharmaceutical...
DUBLIN , June 12, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the closing of its acquisition of EUSA Pharma, a privately-held, specialty pharmaceutical company with a commercial presence in the U.S. and EU and a global distribution network. The a
Read more →JAZZJazz Pharmaceuticals Announces Presentation At The Jefferies 2012 Global Healthcare Conference In New York On June 7 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will make a presentation at the Jefferies 2012 Global Healthcare Conference...
DUBLIN , June 5, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that the company will make a presentation at the Jefferies 2012 Global Healthcare Conference in New York on Thursday, June 7, 2012 at 8:00 a.m. EST / 1:00 p.m. GMT . Bruce Cozadd , Chai
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a conference call and live webcast on Tuesday, May 8, 2012 at 4:30 p.m....
DUBLIN , April 30, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will host a conference call and live webcast on Tuesday, May 8, 2012 at 4:30 p.m. EDT / 9:30 p.m. IST . During the call, company management will provide a business and financi
Read more →JAZZJazz Pharmaceuticals Announces Public Offering of Ordinary Shares by Selling Shareholders Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an underwritten public offering of 7,883,366 of its ordinary shares held by certain of its...
DUBLIN , March 5, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced an underwritten public offering of 7,883,366 of its ordinary shares held by certain of its existing shareholders. Jazz Pharmaceuticals will not receive any proceeds from the sale of or
Read more →JAZZJazz Pharmaceuticals plc Announces New Executive Appointments Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced several senior management appointments that will strengthen and broaden the company's...
DUBLIN , Jan. 24, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced several senior management appointments that will strengthen and broaden the company's leadership team. The appointments include: Additional members of the company's senior management
Read more →JAZZJazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc....
DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc. The two companies have combined to create Jazz Pharmaceuticals plc, a specialty biopharmaceut
Read more →JAZZSEC.gov | Your Request Originates from an Undeclared Automated Tool
The SEC has announced that it will limit requests from undeclared automated tools to ensure equitable access for all users. Users are encouraged to declare their traffic and adhere to guidelines to avoid restrictions on their access.
Read more →JAZZFDA Approves LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) | Jazz Pharmaceuticals plc
The FDA has approved LUVOX CR (fluvoxamine maleate) Extended-Release Capsules for treating social anxiety disorder and obsessive compulsive disorder in adults, providing a new treatment option backed by positive clinical trial results.
Read more →Competitive Position
How JAZZ ranks across every disease it competes inCompetitive Position is a premium feature
See how JAZZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial